ActiveCare (ACARQ) 10-K 14 Jan 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2013	Jan. 13, 2014	Mar. 29, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'ACTIVECARE, INC.	'	'
Document Type	'10-K	'	'
Document Period End Date	30-Sep-13	'	'
Amendment Flag	'false	'	'
Entity Central Index Key	'0001429896	'	'
Current Fiscal Year End Date	'--09-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Common Stock, Shares Outstanding	'	32,860,314	'
Entity Public Float	'	'	$6,000,000

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Balance Sheets	'	'
Cash	$223,835	$529,839
Accounts receivable, net	7,345,912	644,974
Inventory	1,249,220	290,768
Prepaid expenses and other	38,998	7,277
Total current assets	8,857,965	1,472,858
Customer contracts, net of accumulated amortization of $935,361and $102,330, respectively	1,434,521	2,267,552
Goodwill	825,894	825,894
Patents, net of accumulated amortization of $355,458 and $228,587,respectively	566,920	693,790
Equipment leased to customers, net	273,630	312,993
Property and equipment, net	296,730	266,078
Deposits and other assets	106,950	24,634
Domain name, net of accumulated amortization of $2,860 and $2,145,respectively	11,440	12,155
Total assets	12,374,050	5,875,954
Accounts payable	6,621,234	1,132,611
Accounts payable, related-party	251,386	150,395
Accrued expenses	1,253,616	2,104,623
Derivatives liability	795,151	4,015,855
Current portion of notes payable	1,278,585	2,569,221
Current portion of notes payable, related-party	1,892,415	1,563,923
Deferred revenue	13,585	61,608
Dividends payable	3,471	18,322
Total current liabilities	12,109,443	11,616,558
Notes payable, net of current portion	1,055,918	1,804,929
Notes payable, related-party, net of current portion	0	169,857
Total long-term liabilities	1,055,918	1,974,786
Total liabilities	13,165,361	13,591,344
Preferred stock, $.00001 par value: 10,000,000 shares authorized;480,000 and 480,000 shares of Series C; 938,218 and 386,103shares of Series D; and 61,723 and 0 shares of Series E, outstanding, respectively	15	9
Common stock, $.00001 par value: 50,000,000 shares authorized;21,775,303 and 4,636,977 shares outstanding, respectively	220	46
Additional paid-in capital, common and preferred)	62,519,542	29,643,769
Accumulated deficit	-63,311,088	-37,359,214
Total stockholders' deficit	-791,311	-7,715,390
Total liabilities and stockholders' deficit	$12,374,050	$5,875,954

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets Parenthetical (USD $)	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Balance Sheets Parenthetical	'	'
Domain name accumulated amortization	$2,860	$2,145
Patent accumulated amortization	355,458	228,587
Contracted customer accumulated amortization	$935,361	$102,330
Preferred stock par value	$0.00	$0.00
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares outstanding	1,479,941	866,103
Common stock par value	$0.00	$0.00
Common stock shares authorized	50,000,000	50,000,000
Common stock shares outstanding	21,775,303	4,636,977

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statements of Operations	'	'
Chronic Illness Monitoring Revenue	$9,738,988	$706,888
Care Services Revenue	1,660,544	352,223
Total revenues	11,399,532	1,059,111
Chronic Illness Monitoring Cost of Revenue	7,309,999	536,790
Care Services Cost of Revenue	2,325,226	736,520
Total cost of revenues	9,635,225	1,273,310
Gross profit (deficit)	1,764,307	-214,199
Selling, general and administrative (including $2,159,828 and $3,927,214, respectively, of stock-based compensation)	11,039,645	8,855,724
Research and development	832,271	187,230
Total operating expenses	11,871,916	9,042,954
Loss from operations	-10,107,609	-9,257,153
Loss on derivatives liability	-333,406	-2,104,389
Loss on induced conversion of debt and sale of common stock	-9,355,587	0
Interest expense, net	-5,583,932	-858,224
Loss on disposal of property and equipment	-200,149	0
Other expense	-45,011	0
Total other income (expense)	-15,518,085	-2,962,613
Net loss from continuing operations	-25,625,694	-12,219,766
Loss from discontinued operations	-5,312	-145,990
Net loss	-25,631,006	-12,365,756
Dividends on preferred stock	-320,868	-57,183
Net loss attributable to common stockholders	($25,951,874)	($12,422,939)
Continuing operations	($3.52)	($2.89)
Discontinued operations	$0	($0.03)
Net loss per common share	($3.52)	($2.92)
Weighted average common shares outstanding - basic and diluted	7,369,000	4,251,500

Statements_of_Operations_Paren

Statements of Operations Parenthetical (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statements of Operations Parenthetical	'	'
Compensation expense paid in stock or amortization of stock options and warrants	$2,159,828	$3,927,214

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Statements of Cash Flows	'	'
Net loss	($25,631,006)	($12,365,756)
Depreciation and amortization	1,232,734	385,485
Derivatives loss	333,406	2,104,389
Stock-based compensation expense	2,159,828	3,927,214
Stock and warrants issued for services	1,286,999	0
Stock and warrants issued for interest expense	601,220	0
Amortization of debt discounts	3,097,009	418,084
Loss on induced conversion of debt and sale of common stock	9,355,587	0
Loss on disposal of property and equipment	200,149	0
Gain on sale of discontinued operations	-55,096	0
Settlement agreement	0	500,000
Change in accounts receivable	-6,783,896	-527,954
Change in inventories	-1,011,952	-174,758
Change in prepaid expenses and other assets	-16,822	18,101
Change in accounts payable	5,787,603	676,766
Change in accrued expenses	629,879	2,063,859
Change in deferred revenue	-48,023	26,101
Change in deposits and other assets	-82,316	0
Net cash used in operating activities	-8,944,697	-2,948,469
Purchases of property and equipment	-249,771	-47,826
Purchases of equipment leased to customers	-235,917	0
Proceeds from sale of discontinued operations	184,318	0
Proceeds from sale of equipment	4,900	0
Net cash acquired from Green Wire	0	12,215
Acquisition of 4G Biometrics, LLC	0	-350,000
Net cash used in investing activities	-296,470	-385,611
Principal payments on related-party notes payable	-198,606	-165,325
Proceeds from related-party notes payable, net	5,720,799	2,190,000
Proceeds from notes payable, net	3,790,496	1,746,113
Principal payments on notes payable	-1,341,755	-85,000
Proceeds from the sale of common stock, net	981,500	0
Payment of dividends	-17,271	0
Net cash provided by financing activities	8,935,163	3,685,788
Net increase (decrease) in cash	-306,004	351,708
Cash, beginning of the year	529,839	178,131
Cash, end of the year	$223,835	$529,839

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Series C Preferred Stock	Series D Preferred Stock	Series E Preferred Stock	Common stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2011	'	'	'	$39	$24,394,848	($24,936,275)	($541,388)
Balance - shares at Sep. 30, 2011	'	'	'	3,856,816	'	'	3,856,816
Issuance of common stock for services	'	'	'	1	218,905	'	218,906
Issuance of common stock for services - shares	'	'	'	129,161	'	'	129,161
Issuance of common stock for accrued expenses	'	'	'	1	311,999	'	312,000
Issuance of common stock for accrued expenses - shares	'	'	'	60,000	'	'	60,000
Issuance of common stock for loan origination fee	'	'	'	1	69,999	'	70,000
Issuance of common stock for loan origination fee - shares	'	'	'	100,000	'	'	100,000
Issuance of common stock for debt conversion	'	'	'	1	92,399	'	92,400
Issuance of common stock for debt conversion - shares	'	'	'	231,000	'	'	231,000
Issuance of common stock for settlement agreement	'	'	'	2	499,998	'	500,000
Issuance of common stock for settlement agreement - shares	'	'	'	200,000	'	'	200,000
Issuance of Series D preferred stock for debt conversion	'	1	'	'	109,999	'	110,000
Issuance of Series D preferred stock for debt conversion - shares	'	55,000	'	'	'	'	55,000
Issuance of Series D preferred stock for loan origination fee	'	1	'	'	389,999	'	390,000
Issuance of Series D preferred stock for loan origination fee - shares	'	140,000	'	'	'	'	140,000
Issuance of Series D preferred stock for acquisitions	'	2	'	'	679,998	'	680,000
Issuance of Series D preferred stock for acquisitions - shares	'	180,000	'	'	'	'	180,000
Issuance of Series D preferred stock for dividends	'	'	'	'	38,861	'	38,861
Issuance of Series D preferred stock for dividends - shares	'	11,103	'	'	'	'	11,103
Stock based compensation	'	'	'	'	3,708,308	'	3,708,308
Issuance of options for loan origination fees	'	'	'	'	'	'	117,551
Issuance of options for laon origination fees	'	'	'	'	117,551	'	117,551
Derivatives liabilites	'	'	'	'	-1,911,466	'	-1,911,466
Issuance of common and Series C preferred stock for patents	5	'	'	1	922,371	'	922,377
Issuance of common and Series C preferred stock for patents - shares	480,000	'	'	60,000	'	'	540,000
Net loss	'	'	'	'	'	-12,365,756	-12,365,756
Dividends on preferred stock	'	'	'	'	'	-57,183	-57,183
Issuance of common stock for dividends	'	'	'	'	'	'	38,861
Balance at Sep. 30, 2012	5	4	'	46	29,643,769	-37,359,214	-7,715,390
Balance - shares at Sep. 30, 2012	480,000	386,103	'	4,636,977	'	'	5,503,080
Issuance of common stock for services	'	'	'	16	475,484	'	475,500
Issuance of common stock for services - shares	'	'	'	1,579,632	'	'	1,579,632
Issuance of common stock for accrued expenses	'	'	'	2	225,298	'	225,300
Issuance of common stock for accrued expenses - shares	'	'	'	166,200	'	'	166,200
Issuance of common stock for loan origination fee	'	'	'	2	334,265	'	334,267
Issuance of common stock for loan origination fee - shares	'	'	'	189,345	'	'	189,345
Issuance of common stock for debt conversion	'	'	'	136	18,466,987	'	18,467,123
Issuance of common stock for debt conversion - shares	'	'	'	13,439,190	'	'	13,439,190
Issuance of Series D preferred stock for loan origination fee	'	1	'	'	817,482	'	817,483
Issuance of Series D preferred stock for loan origination fee - shares	'	103,843	'	'	'	'	103,843
Issuance of Series D preferred stock for dividends	'	'	'	'	66,881	'	66,881
Issuance of Series D preferred stock for dividends - shares	'	14,087	'	'	'	'	14,087
Stock based compensation	'	'	'	'	1,750,274	'	1,750,274
Issuance of options for loan origination fees	'	'	'	'	289,732	'	289,732
Derivatives liabilites	'	'	'	'	4,417,456	'	4,417,456
Issuance of common and Series C preferred stock for patents	'	'	'	'	'	'	0
Net loss	'	'	'	'	'	-25,631,006	-25,631,006
Dividends on preferred stock	'	'	'	'	'	-320,868	-320,868
Issuance of common stock for cash	'	'	'	13	1,838,820	'	1,838,833
Issuance of common stock for cash - shares	'	'	'	1,313,334	'	'	1,313,334
Issuance of common stock for dividends	'	'	'	2	251,562	'	251,564
Issuance of common stock for dividends - shares	'	'	'	200,625	'	'	200,625
Issuance of Series D preferred stock for services	'	5	'	'	1,800,526	'	1,800,531
Issuance of Series D preferred stock for services - shares	'	484,185	'	'	'	'	484,185
Issuance of Series E preferred stock for debt conversions	'	'	1	'	614,764	'	614,765
Issuance of Series E preferred stock for debt conversions - shares	'	'	61,723	'	'	'	61,723
Issuance of options for services	'	'	'	'	202,572	'	202,572
Beneficial conversion features on debt	'	'	'	'	1,323,672	'	1,323,672
Conversion of Series D preferred stock	'	-1	'	3	-2	'	'
Conversion of Series D preferred stock - shares	'	-50,000	'	250,000	'	'	200,000
Balance at Sep. 30, 2013	$5	$9	$1	$220	$62,519,542	($63,311,088)	($791,311)
Balance - shares at Sep. 30, 2013	480,000	938,218	61,723	21,775,303	'	'	23,255,244

1_Organization_and_Nature_of_O

1. Organization and Nature of Operations	12 Months Ended
	Sep. 30, 2013
Notes	'
1. Organization and Nature of Operations	'
	1.       Organization and Nature of Operations
	ActiveCare, Inc. ( “ActiveCare”) was formed March 5, 1998 as a wholly owned subsidiary of SecureAlert, Inc. [OTCBB: SCRA.OB], a Utah corporation, formerly known as RemoteMDx, Inc. (“SecureAlert”).  ActiveCare was spun off from SecureAlert in February 2009 and SecureAlert retained no ownership interest in ActiveCare.  In July 2009, ActiveCare was reincorporated in Delaware.  ActiveCare and its wholly owned subsidiaries (collectively “the Company”) is a technology and service provider that provides real-time visibility to health conditions and risk, and has a unique active approach in caring for members, resulting in improved outcomes.
	Going Concern
	Although the Company had positive gross margin for fiscal year 2013, it has incurred negative cash flows from operating activities, recurring net losses, negative working capital, and negative total equity.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	In order for the Company to remove substantial doubt about its ability to continue as a going concern, it must improve gross margins, generate positive cash flows from operating activities, and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management’s plans with respect to this uncertainty include raising additional capital by issuing equity securities and increasing the sales of the Company’s services and products.  Subsequent to year end, the Company (1) completed the sale of $3,120,000 of 8% Series F variable rate convertible preferred stock (“Series F preferred stock”); (2) converted $2,301,801 of debt and accrued interest to common stock; and (3) converted $573,886 of debt and accrued interest to Series F variable rate convertible preferred stock (see Note 20). There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to offset operating losses.  If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and may have to cease operations.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2013
Notes	'
2. Summary of Significant Accounting Policies	'
	2.     Summary of Significant Accounting Policies
	Principles of Accounting and Consolidation
	These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”).  The consolidated financial statements include the accounts of ActiveCare and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated.
	Use of Estimates in the Preparation of Financial Statements
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.
	In May 2013, the Company effected a 10-for-1 reverse common stock split.  The consolidated financial statements and notes for all periods presented have been retroactively adjusted to reflect the reverse common stock split.
	Discontinued Operations
	In June 2013, the Company sold the net assets and operations of its reagents business segment to a third party for $184,318 in cash.  During fiscal years 2013 and 2012, the Company recognized a loss from discontinued operations of $5,312 and $145,990, respectively.
	Fair Value of Financial Instruments
	The carrying values of cash, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature and liquidity of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. Based on current market condition, the Company estimates the fair values of its long-term debt obligations approximate their carrying values as of September 30, 2013.
	Concentrations of Credit Risk
	The Company has cash in bank accounts that, at times, may exceed federally insured limits.  The Company has not experienced any losses in these accounts.
	In the normal course of business, the Company provides credit terms to its customers and requires no collateral.  The Company performs ongoing credit evaluations of its customers’ financial condition.  The Company maintains an allowance for doubtful accounts receivable based upon management’s specific review and assessment of each account at the period end.
	During fiscal year 2013, the Company had revenues from three significant Chronic Illness Monitoring customers, which represented 72% of total revenue.  As of September 30, 2013, accounts receivable from significant customers represented 92% of total accounts receivable.  During fiscal year 2012, the Company had revenues from one significant Chronic Illness Monitoring customers, which represented 28% of total revenues.  As of September 30, 2012, accounts receivable from the significant customer represented 51% of total accounts receivable.
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts.  Specific reserves are estimated by management based on certain assumptions and variables, including the customer’s financial condition, age of the customer’s receivables and changes in payment histories.  Accounts receivable are written off when management determines the likelihood of collection is remote.  A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date.  Interest is not charged on accounts receivable that are past due.  The Company recorded an allowance for doubtful accounts of $76,544 and $20,195 as of September 30, 2013 and 2012, respectively.
	Inventories
	Inventories are recorded at the lower of cost or market, cost being determined using the first-in, first-out (“FIFO”) method. Chronic Illness Monitoring inventory consists of diabetic supplies.  The Company writes down inventory for obsolescence and excessive levels to estimated net realizable value.  Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term.  Inventories consist of the following as of September 30:
					2013		2012
	Chronic Illness Monitoring
		Finished goods		$	1,249,220	$	185,884
	Careservices
		ActiveHomeTM			-		56,767
	Reagents
		Raw materials			-		36,211
		Work in process			-		5,745
		Finished goods			-		6,161
			Total inventories	$	1,249,220	$	290,768
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization.  Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years.  Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease.  Expenditures for maintenance and repairs are expensed as incurred.  Upon the sale or disposal of property and equipment, any gains or losses are included in the results of operations.
	Equipment Leased to Customers
	Leased equipment is stated at cost less accumulated depreciation and amortization.  The Company amortizes the cost of leased equipment on a straight-line basis over 36 months, which is the estimated useful life of the equipment.  Amortization of leased equipment is recorded as cost of revenues.
	Goodwill
	Goodwill is not amortized but is reviewed for potential impairment at least annually.  The identification and measurement of goodwill impairment involves the estimation of the fair value of the Company’s reporting units.  The estimates of fair value of reporting units are based on the best information available as of the date of the assessment and incorporate management assumptions about expected future cash flows.  Future cash flows can be affected by changes in Company performance, industry or market conditions, or overall economic trends.  Management determined goodwill that was not impaired during fiscal years 2013 or 2012.
	Impairment of Long-Lived Assets
	Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets, which range from 2 to 20 years.  Long-lived assets, including intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.  Management determined that long-lived assets were not impaired during fiscal years 2013 or 2012.
	Revenue Recognition
	The Company’s revenue has historically been from three sources: (i) sales from Chronic Illness Monitoring services and supplies; (ii) sales from CareServices; and (iii) sales of medical diagnostic stains from the reagents segment, which was sold during fiscal year 2013 and reported as discontinued operations.
	Chronic Illness Monitoring
	The Company began chronic illness monitoring sales as a result of its acquisition of 4G Biometrics, LLC in the quarter ended March 31, 2012 (see Note 4).  The Company recognizes Chronic Illness Monitoring revenue when persuasive evidence of an arrangement with the customer exists, title passes to the customer, prices are fixed or determinable, and collection is reasonably assured.
	Shipping and handling billed to customers are included in revenues.  The related freight costs and supplies directly associated with shipping products to customers are included as a component of cost of revenues.  Sales of Chronic Illness Monitoring products and services do not contain multiple deliverables.
	The Company enters into agreements with insurance companies, disease management companies, and self-insured companies (collectively, customers) to lower medical expenses by distributing diabetic testing supplies to their customers or employees (members) and monitoring their test results.  Customers are obligated to pay for the supplies at the time of shipment and cash is due from these customers as the product is deployed to the members.  The terms of these contracts are generally one year and, unless terminated by either party, will automatically renew for another year.  Collection terms are net 30-days after claims are submitted.
	Revenue is recognized on the date of sale because the following exist:
	·         The price to the contracted customer is fixed or determinable at the date of sale.
	·         The customer has paid or is obligated to pay the Company within terms.
	·         The customer’s obligation to the Company is not changed in the event of theft or physical destruction or damage of the product.
	·         Once the product is shipped, there is no right of return.
	CareServices
	The “CareServices” segment sells devices to distributors as well as provides monitoring services to end users on a contractual basis.  The Company typically enters into contracts on a month-to-month basis with customers (members) that use the Company’s CareServices.  However, either party may cancel these contracts at any time with 30-days notice.  Under the Company’s standard contract, the device becomes billable on the date the member orders the product, and remains billable until the device is returned to the Company.  The Company recognizes revenue on devices at the end of each month that CareServices have been provided.  In those circumstances in which the Company receives payment in advance, the Company records these payments as deferred revenue.
	The Company recognizes CareServices revenue when persuasive evidence of an arrangement with the customer exists, title passes to the customer, prices are fixed or determinable, and collection is reasonably assured.  Shipping and handling fees billed to the customer are included in revenues.  The related freight costs and supplies directly associated with shipping products to members are included as a component of cost of revenues.  All CareServices sales are made with net 30-day payment terms.
	Revenue is recognized on the date of sale because the following exist:
	·         The price to the customer is fixed or determinable at the date of sale.
	·         The customer has paid or is obligated to pay within terms, and the obligation is not contingent on resale of the product.
	·         The customer’s obligation is not changed in the event of theft or physical destruction or damage of the product.
	·         The customer acquiring the product for resale has economic substance apart from the Company.
	·         The Company does not have significant obligations for future performance to bring about resale of the product by the customer.
	·         The amount of future returns are estimatable and are not significant.
	The vast majority of CareServices revenues are for services.  Because equipment sales are not material, the Company presents services and equipment sales together in the accompanying financial statements.
	The Company’s distributors are not required to maintain specified amounts of product on hand, and distributors are not required to make minimum purchases to maintain distributor status.  Distributors have no stock rotation rights or additional rights of return.  Revenues from products sold with long-term service contracts are recognized ratably over the expected life of the contract.  Revenues are recorded net of estimated returns and discounts.
	Reagents
	Prior to the sale of the reagent segment, the Company recognized reagents revenues when persuasive evidence of an arrangement with the customer existed, title passed to the customer, prices were fixed or determinable, and collection was reasonably assured.  Prior to the sale of the reagent segment, shipping and handling fees billed to customers were included in revenues and the related freight costs and supplies directly associated with shipping products to customers were included as a component of cost of revenues.
	Research and Development Costs
	All expenditures for research and development are charged to expense as incurred. Research and development expenses for fiscal years 2013 and 2012 were $832,271 and $187,230, respectively. The expenditures for fiscal year 2013 were primarily for the development of the Chronic Illness Monitoring operating system. The expenditures for fiscal year 2012 were for software development efforts for the chronic illness market.
Advertising Costs
The Company expenses advertising costs as incurred.  Advertising expenses for fiscal years 2013 and 2012 were $59,330 and $176,300, respectively.  Advertising expenses primarily relate to the Company’s Chronic Illness Monitoring segment.
Income Taxes
The Company recognizes deferred income tax assets or liabilities for the expected future tax consequences of events that have been recognized in the financial statements or income tax returns. Deferred income tax assets or liabilities are determined based upon the difference between the financial reporting bases and tax reporting bases of assets and liabilities using enacted tax rates expected to apply when the differences are expected to be settled or realized.  Deferred income tax assets are reviewed periodically for recoverability and valuation allowances are provided as necessary.  As of September 30, 2013, management has determined to provide a 100% allowance against deferred income tax assets as it is more likely than not these assets will not be realized.  Interest and penalties related to income tax liabilities, when incurred, are classified in interest expense and income tax provision, respectively.
Warrant Exercises
The Company issues common shares in connection with warrant exercises when it has received verification that the proceeds have been deposited and when it has received an exercise letter from the warrant holder.  The Company issues common shares in connection with note conversion after it verifies the outstanding note balance and the eligibility of conversion, and has received a conversion letter from the lender.
Stock-Based Compensation
The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the statement of operations over the period during which the employee is required to provide service in exchange for the award – the requisite service period.  The grant-date fair values of the equity instruments are estimated using option-pricing models adjusted for the unique characteristics of those instruments.
Net Loss Per Common Share
Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the year.
Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss available to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive common share equivalents then outstanding.  The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect.
Common share equivalents consist of shares issuable upon the exercise of common stock warrants, shares issuable from restricted stock grants, shares issuable from convertible notes and convertible Series C, Series D and Series E preferred stock.  As of September 30, 2013 and 2012, there were 13,127,396 and 8,202,219 outstanding common share equivalents, respectively, that were not included in the computation of Diluted EPS as their effect would be anti-dilutive.  The common stock equivalents outstanding consist of the following as of September 30:
		2013		2012
Common stock options and warrants		3,598,554		2,386,587
Series C convertible preferred stock		480,000		480,000
Series D convertible preferred stock		4,691,090		1,830,515
Series E convertible preferred stock		601,585		-
Convertible debt		3,738,917		3,444,217
Restricted shares of common stock		17,250		60,900
	Total common stock equivalents	13,127,396		8,202,219
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year’s presentation.  The reclassification had no effect on the previously reported net loss.
Recent Accounting Pronouncements
The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and has concluded that the future adoption of any such pronouncements will not have a material impact on the Company’s financial position, results of operations, or liquidity.

3_Discontinued_Operations

3. Discontinued Operations	12 Months Ended
	Sep. 30, 2013
Notes	'
3. Discontinued Operations	'
	3.     Discontinued Operations
	In June 2013, the Company sold its assets and liabilities related to the reagents segment.  This segment was engaged in the business of manufacturing and marketing medical diagnostic stains, solutions and related equipment to hospitals and medical testing labs.  The purchaser was a former employee.  The sale consisted solely the Company's reagents business.
	The Company no longer holds any ownership interest in the reagents segment and has ceased incurring costs related to its operations and development. The sale included all applicable segment assets and liabilities including, accounts receivable, inventory, accounts payable, property, equipment and leased equipment.  The purchaser also assumed the lease for general office and warehouse space.
	As a result of the sale of the reagents business, the Company has reflected this segment as discontinued operations in the consolidated financial statements for fiscal years 2013 and 2012.  The following table summarizes certain operating data for discontinued operations for fiscal years 2013 and 2012:
			2013		2012
	Revenues	$	351,645	$	467,259
	Cost of revenues		(300,396)		(392,049)
	Gross margin		51,249		75,210
	Selling, general and administrative expenses		(111,657)		(221,200)
	Loss from discontinued operations		(60,408)		(145,990)
	Gain on sale discontinued operations		55,096		-
	Net loss from discontinued operations	$	(5,312)	$	(145,990)

4_Acquisitions

4. Acquisitions	12 Months Ended
	Sep. 30, 2013
Notes	'
4. Acquisitions	'
	4. Acquisitions
	4G Biometrics, LLC
	On March 8, 2012, the Company acquired 4G Biometrics, LLC, a Texas limited liability company (“4G”).  Pursuant to the acquisition agreement, the Company acquired 100 percent of the member interests of 4G and 4G is operated as a wholly owned subsidiary of the Company.  The consideration for the member interests of 4G was comprised as follows:
	·         $350,000 in cash;
	·         The assumption of $50,000 of accounts payable and accrued liabilities;
	·         160,000 shares of Series D convertible preferred stock;
	·         Options for the purchase of up to 433,333 shares of common stock of the Company at $1.00 per share to each of the three sellers with vesting as follows:
	o    Options for 43,333 shares vest when 4G has 9,300 members
	o    Options for another 43,333 shares vest when an additional 5,000 4G members are added, or a total of 14,300 members;
	o    Options for another 43,333 shares vest when an additional 5,000 4G members are added, or a total of 19,300 members;
	o    Options for another 43,333 shares vest when an additional 5,000 4G members are added, or a total of 24,300 members; and
	o    so forth until fully vested.
	As of September 30, 2013, options to purchase 260,000 shares of common stock have vested.
	Three of the 4G key operational managers are under two-year written employment agreements with the Company.
	Under the purchase method of accounting, the purchase price was allocated to 4G’s assets and assumed liabilities based on their estimated fair values as of the closing date of the acquisition.  The excess of the purchase price over the fair values of the net assets acquired was recorded as goodwill.
	The purchase price for 4G reflects total consideration paid of $1,040,000, of which $825,894 was allocated to goodwill and $214,106 was allocated to customer contracts.
	GWire
	During fiscal year 2012, the Company established GWire Corporation (“GWire”) as a subsidiary.  Effective September 1, 2012, GWire acquired the assets and assumed certain liabilities of Green Wire, LLC, Green Wire Outsourcing, Inc., Orbit Medical Response, LLC, and Rapid Medical Response, LLC (collectively, “Green Wire”).  The Company entered into employment agreements with two of Green Wire’s operating managers on November 1, 2012. These two individuals were granted 27% ownership in GWire and ActiveCare retained the remaining 73%.  The purchase consideration for Green Wire consisted of the following:
	·         $2,236,737 in the form of a note payable with a 36-month initial term (including imputed interest at 12%); and
	·         20,000 shares of ActiveCare’s Series D convertible preferred stock, valued at $40,000.
	Under the purchase method of accounting, the purchase price for Green Wire was allocated to the assets purchased and liabilities assumed based on their estimated fair values as of the closing date of the acquisition.
	The purchase price for Green Wire reflects total consideration paid of $2,276,737, which has been allocated to $12,215 of cash, $13,976 of accounts receivable, $92,022 of property and equipment, $16,964 of deposits and other assets, $229,249 of leased equipment, $2,155,776 of customer contracts, $154,206 of accounts payable, $55,117 of accrued expenses and $34,142 of deferred revenue.
	During fiscal year 2013, the two operating managers converted their 27% ownership in GWire and 425,000 of related options into 425,000 shares of the Company’s common stock.  As a result, the Company owns 100% of GWire as of September 30, 2013.

5_Property_Plant_and_Equipment

5. Property, Plant and Equipment Disclosure	12 Months Ended
	Sep. 30, 2013
Notes	'
5. Property, Plant and Equipment Disclosure	'
	5. Property and Equipment
	Property and equipment consisted of the following as of September 30:
				2013		2012
	Equipment		$	255,339	$	374,229
	Leasehold improvements			145,147		402,016
	Software			87,361		65,111
	Furniture			32,855		50,123
		Total gross property and equipment		520,702		891,479
	Accumulated depreciation and amortization			(223,972)		(625,401)
		Property and equipment, net	$	296,730	$	266,078
	Assets to be disposed of are reported at the lower of the carrying amounts or fair values, less the estimated costs to sell or dispose.  During fiscal years 2013 and 2012, the Company recorded a loss on the disposal of assets of $200,149 and $0, respectively, and disposed of $25,832 of assets related to the sale of the Reagents segment during fiscal year 2013. Depreciation expense for fiscal years 2013 and 2012 was $97,068 and $64,632, respectively.

6_Patent_License_Agreement

6. Patent License Agreement	12 Months Ended
	Sep. 30, 2013
Notes	'
6. Patent License Agreement	'
	6. Patent License Agreement
	During fiscal year 2009, the Company licensed the use of certain patents from a third party.  Under the license agreement, the Company was required to pay $300,000 plus a 5% royalty on the net sales of all licensed products. As of September 30, 2009, the Company had capitalized the initial license fee as a long-term asset and had recorded a corresponding current liability as the fee was not yet paid.
	During fiscal year 2012, the Company agreed to purchase the related patents and settle amounts owed under the license agreement by issuing 600,000 shares of common stock and 480,000 shares of Series C preferred stock.  The patents were valued at $922,378, based on a valuation performed by an independent valuation expert.  The value of the common stock issued was $240,000, based on the market price of the common stock on the date of issuance. The implied value of the Series C was $682,378, which was based on the difference between the value of the patents and the common stock issued in settlement of the existing liability.
	The Company is amortizing the patents over their remaining useful lives (through 2018).  Amortization expense for fiscal years 2013 and 2012 was $126,870 and $147,277, respectively.  The Company’s future patent amortization as of September 30, 2013, is as follows:
	Years Ending September 30,
	2014	$	126,870
	2015		126,870
	2016		126,870
	2017		126,870
	2018		59,440
		$	566,920

7_Customer_Contracts

7. Customer Contracts	12 Months Ended
	Sep. 30, 2013
Notes	'
7. Customer Contracts	'
	7. Customer Contracts
	During the fiscal year ended 2012, the Company recorded customer contracts of $2,369,882 acquired in its purchase of 4G and GWire.  The Company is amortizing the customer contracts over their estimated useful lives (through 2015).  Amortization expense for fiscal years 2013 and 2012 was $833,032 and $102,329, respectively.  The Company’s future customer contract amortization as of September 30, 2013, is as follows:
	Years Ending September 30,
	2014	$	775,812
	2015		658,709
		$	1,434,521

8_Equipment_Leased_to_Customer

8. Equipment Leased to Customers	12 Months Ended
	Sep. 30, 2013
Notes	'
8. Equipment Leased to Customers	'
	8. Equipment Leased to Customers
	Equipment leased to customers consisted of the following as of September 30:
			2013		2012
	Leased equipment	$	389,492	$	457,898
	Accumulated depreciation		(115,862)		(144,905)
	Leased equipment, net	$	273,630	$	312,993
	The Company leases monitoring equipment to customers for CareServices.  The leased equipment is depreciated using the straight-line method over the 3-year estimated useful lives of the related equipment, regardless of whether the equipment is leased to a customer or remaining in stock.  Leased equipment depreciation expense for fiscal years 2013 and 2012 was $175,049 and $70,531, respectively.  The depreciation expense is recorded in cost of revenues for CareServices. Customers have the right to cancel the service agreements at any time.  During fiscal years 2013 and 2012, the Company recorded a loss on the disposal of leased equipment of $75,124 and $0, respectively.

9_Notes_Payable

9. Notes Payable	12 Months Ended
	Sep. 30, 2013
Notes	'
9. Notes Payable	'
	9. Notes Payable
	The Company had the following notes payable outstanding as of September 30:
		2013		2012
	Note payable to the former owners of Green Wire, secured by customer contracts, imputed interest rate of 12%, with monthly installments over a 38-month term.  In March 2013, the Company issued 15,000 shares of common stock to extend two past due payments without penalty and the grant date fair value was $24,000, which will be amortized over the remaining life of the note.	$         1,766,971		$         2,236,737
	Notes payable with interest at 12%, secured by the Company's assets, due August 2014 and convertible into the shares of common stock at $0.75 per share.  The notes required $51,250 in due diligence and legal fees.  The Company issued warrants to purchase 36,667 shares of common stock as due diligence fees with a grant date fair value of $51,452.  The Company issued 25,000 shares of common stock with a grant date fair value of $31,250 to a related party as consideration for signing a personal guarantee.  The notes and accrued interest were converted to Series F preferred stock subsequent to September 30, 2013 (see note 20).	550,000		-
	Unsecured note with interest at 12%, due March 2013.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	250,000		250,000
	Unsecured notes with interest at 15% (18% after due date), due March and April 2013, respectively.  The Company issued 20,000 shares of Series D preferred stock as loan origination fees with a grant date fair value of $195,000.   Principal of $50,000 was converted to common stock subsequent to September 30, 2013 (see note 20).	185,476		-
	Series A debenture loans payable, secured by customer contracts and payable in 36 monthly installments, original due dates between September and April 2016. The loans bear interest at 12% and are convertible into common stock after 180 days.  After payment of principal and interest, the holders of the Series A and Series B debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out each lender's royalty by paying the respective lender $20,000 for every $25,000 loaned.  The note included a beneficial conversion feature valued at $901,000 at inception, which the Company is amortizing over the life of the loan.  The feature had an unamortized value of $47,934 as of September 30, 2013.  The majority of loans were converted during fiscal year 2013.   The remaining balance was converted to Series E preferred stock subsequent to September 30, 2013 (see note 20).	85,719		300,000
	Unsecured note with interest at 15%, due March 2013, currently in default. Note included a $25,000 cash and 100,000 shares of common stock as loan origination fees with a grant date fair value of $70,000.   The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	25,000		275,000
	Unsecured note with interest at 15% (18% after due date), due November 2012.  The Company issued 60,000 shares of Series D stock as loan origination fees with a grant date fair value of $150,000.  The note was guaranteed by the Company’s Chief Executive Officer.	-		1,500,000
	Total before discount and current portion	2,863,166		4,561,737
	Less discount	(528,663)		(187,587)
	Total notes payable	2,334,503		4,374,150
	Less current portion	(1,278,585)		(2,569,221)
	Total notes payable, net of current portion	$         1,055,918		$         1,804,929
	Scheduled principal payments on notes payable are as follows:
	Years Ending September 30,
	2014	$	1,768,820
	2015		854,522
	2016		239,824
		$	2,863,166

10_Relatedparty_Notes_Payable

10. Related-party Notes Payable	12 Months Ended
	Sep. 30, 2013
Notes	'
10. Related-party Notes Payable	'
	10. Related-Party Notes Payable
	The Company had the following related-party notes payable outstanding as of September 30:
		2013	2012
	Unsecured notes payable to an entity controlled by an officer of the Company with interest at 15% (18% in the event of default), due September 30, 2013.  The Company issued 60,000 shares of common stock as loan origination fees with a grant date fair value of $93,000.  The notes and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	$            600,000	$                     -
	Unsecured note payable to an entity controlled by an officer of the Company, with interest at 3% (18% in the event of default), due July 2013.  In July the lender agreed to extend the maturity date to September 30, 2013 with an interest at 12% (18% in the event of default).  The Company issued 30,000 shares of common stock with grant date fair value of $38,100 as loan origination fees.  In the event of default, the note is convertible into share of common stock at $0.75 per share. The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	300,000	-
	Unsecured note payable to an entity controlled by an officer of the Company, interest at 12% (18% in the event of default), due September 30, 2013.  The Company issued 30,000 shares of common stock with a grant date fair value of $37,500 as loan origination fees.  In the event of default, the note is convertible into shares of common stock at $0.75 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	300,000	-
	Unsecured notes payable to an entity controlled by an officer of the Company, interest at 12% (18% in the event of default), due April 2013.  In the event of default, the note is convertible into shares of common stock at $0.40 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	200,000	-
	Unsecured note payable to a lender under the control of the Company’s CEO, interest at 12%, due upon demand. The note is convertible into shares of common stock at $0.75 per share.  The Company recognized $148,750 in connection with the beneficial conversion feature.  The Company issued 17,500 shares of common stock with a grant date fair value of $26,250 as loan origination fees.  Subsequent to September 30, 2013 $160,000 of the note was converted to common stock (see note 20).	175,000	-
	Unsecured note payable with zero interest to an entity controlled by an officer of the Company.  The note was repaid in full subsequent to September 30, 2013.	150,000	-
	Unsecured note payable to an entity controlled by an officer of the Company, with interest at 12%, due August 2012.   During fiscal year 2013, the lender agreed to extend the maturity date to June 30, 2013 with an interest at 18% and 5,600 shares of Series D with a grant date fair value of $56,252 paid as a loan origination fee.  The note is currently in default.  The note also included $7,500 of loan origination fees added to the principal. In the event of default, the note is convertible into shares common stock at $0.40 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	82,500	543,278
	Unsecured note payable to an officer of the Company with interest at 15%, due June 2012, currently in default.  The note includes $3,000 of loan origination fees added to the principal and is convertible into common stock at $0.50 per share.	33,000	33,000
	Unsecured note payable to an officer of the Company with interest at 12%, due September 30, 2013, currently in default.  The loan is convertible into the Company's common stock at a rate of $0.75 per share.  The Company recognized $22,820 in connection with the beneficial conversion feature.	26,721	-
	Unsecured note payable to an officer of the Company with interest at 12%, due upon demand.	13,644	-
	Unsecured notes payable with zero interest to an individual related to an officer of the Company.  The loan was repaid in full subsequent to September 30, 2013.	10,000	-
	Series B unsecured debenture loans from entities controlled by an officer of the Company, including $68,914 in loan origination fees added to the principal of the loans, payable in 36 monthly installments, maturing December 2015 and January 2016.  Of the debenture, $554,556 was issued to settle a related-party note payable with a total outstanding balance of $460,778 and $43,364 of related accrued interest.  Of the loan, $35,000 was issued to settle an accrued service fee.  The loans bear interest at 12% and are convertible into common stock after 180 days. After payment of principal and interest, the holders of the Series B and Series A debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out the royalty by paying the lender $22,000 for every $25,000 loaned.  During the fiscal year ended September 30, 2013, the Company issued 34,400 shares of Series D with a fair market value of $343,748 at date of grant as additional loan origination fees, and paid $30,102 of the loan principal.  The Company is late on certain monthly payments.  The notes include beneficial conversion features valued at $167,000 at inception, which the Company is amortizing over the life of the loan.  The feature had an unamortized value of $3,348 as of September 30, 2013.  During fiscal year 2013, $722,684 of outstanding principal and $49,895 of accrued interest were converted into 1,030,107 common shares at a rate of $0.75 per share.  The Company recorded $535,656 of expense associated with the induced conversion of these debenture loans. The majority of loans were converted during fiscal year 2013.  The remaining note of $5,270 and accrued interest were converted to common stock subsequent to September 30, 2013 (see note 20)	5,270	-
	Unsecured notes payable to a lender under the control of the Company’s CEO with a line of credit borrowing capacity of $2,000,000, interest at 12%, due July 2013. The notes were convertible into shares of common stock at $5.00 per share.  In connection with the notes payable, the Company issued 80,000 shares of Series D preferred stock (valued at $240,000).  The Company granted warrants to purchase 341,000 shares of common stock as a loan origination fee. These warrants vested immediately and are exercisable at $4.40 per share through November 3, 2016. The fair value of the warrants was $107,130, and was measured using a binomial valuation model with the following assumptions: exercise price $4.40; risk-free interest rate of .39%; expected life of 2.5 years; expected dividends of zero; a volatility factor of 134.57%; and market price on date of grant of $4.40.  During fiscal year 2012, the Company re-priced the exercise price of the warrants from $4.40 to $1.00 per share.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the lender in satisfaction of the outstanding balance of $620,687 plus $21,585 of accrued interest.  Upon the conversion of the note, the Company immediately recognized the unamortized debt discount of $209,143.	-	620,687
	Note payable to an entity controlled by an officer of the Company, interest at 12%, due December 2012.  This note was secured by real estate.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $300,000 plus $14,992 of accrued interest.	-	300,000
	Series A debenture loans from a former CEO and Chairman of the Company, secured by customer contracts, payable in 36 monthly installments, maturing September and December 2015.  The loans bear interest at 12% and are convertible into common stock after 180 days. After payment of principal and interest, the holders of the Series B and Series A debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out each royalty by paying the lender $20,000 for every $25,000 loaned.  During fiscal year 2013, the Company paid $41,682 of the loan principal.  During fiscal year 2013, $342,912 of principal and interest were converted into 457,216 common shares.  The Company recorded $297,191 of expense associated with the induced conversion of these notes.	-	244,196
	Unsecured note payable to an entity controlled by an officer of the Company, including a $7,500 loan origination fee, interest at 12%, due August 2012.  The note was convertible into common stock at 50% of fair market value or $0.40 per share, whichever is less.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $82,500 plus $3,716 of accrued interest.	-	82,500
	Unsecured note payable to an entity controlled by an officer of the Company, including a $7,500 loan origination fee, interest at 12%, due September 2012. The note was convertible into common stock at $0.40 per share or 50% of market value, whichever was less.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $82,500 plus $3,173 of accrued interest.	-	82,500
	Notes payable to an entity controlled by an officer of the Company, including a $26,000 loan origination fee which was convertible into Series D preferred stock at any time at $2.00 per share, interest at 15%, due December 2012.  This note was secured by real estate.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $51,000 plus $3,186 of accrued interest.  Upon the conversion of the note, the Company immediately recognized the unamortized debt discount of $14,238.	-	51,000
	Total before discount and current portion	1,896,135	1,957,161
	Less discount	(3,720)	(223,381)
	Total notes payable, related-party	1,892,415	1,733,780
	Less current portion	(1,892,415)	(1,563,923)
	Total  notes payable, related-party, net of current portion	$                     -	$            169,857
	The total principal on related-party notes payable of $1,892,415 is schedule to be repaid during the fiscal year ending September 30, 2014.

11_Loss_On_Induced_Conversion_

11. Loss On Induced Conversion of Debt and Sale of Common Stock	12 Months Ended
	Sep. 30, 2013
Notes	'
11. Loss On Induced Conversion of Debt and Sale of Common Stock	'
	11. Loss on Induced Conversion of Debt and Sale of Common Stock
	The Company offered an induced conversion rate to all debt holders at a rate of $0.75 per share of common stock, which was below the market price of the stock.  Debt and accrued interest of approximately $10,004,000 was converted to shares of common stock. The Company also offered the private placement of common stock to existing investors at $0.75 per share, which was below the market price.  The difference between the offered price and the market price of all common stock issued was approximately $9,356,0009355587 and is recorded as a loss on induced conversion of debt and sale of common stock.

12_Fair_Value_Measurements

12. Fair Value Measurements	12 Months Ended
	Sep. 30, 2013
Notes	'
12. Fair Value Measurements	'
	12. Fair Value Measurements
	The Company measured the fair values of its assets and liabilities using the US GAAP hierarchy levels as follows:
	Level 1	The Company does not have any Level 1 inputs available to measure its assets.
	Level 2	The Company’s embedded derivative liabilities are measured on a recurring basis using Level 2 inputs.
	Level 3	The Company’s goodwill is measured using Level 3 inputs.
	The Company’s embedded derivative liabilities are re-measured to fair value as of each reporting date until the contingency is resolved.  See Note 13 below for more information about these liabilities and the inputs used for calculating fair value.

13_Derivative_Liabilities

13. Derivative Liabilities	12 Months Ended
	Sep. 30, 2013
Notes	'
13. Derivative Liabilities	'
	13. Derivative Liabilities
	As described in Notes 9 and 10, the Company has issued convertible notes payable with variable conversion options.  The Company has determined the conversion options of certain notes payable are subject to derivative liability treatment and are required to be accounted for at fair value.  The derivative liabilities for the fiscal years ended September 30, 2013 and 2012 totaled $795,151 and $4,015,855, respectively.  The derivative liability as of September 30, 2012 was eliminated during fiscal year 2013 as a result of the 10-for-1 reverse common stock split, this decreased the number of outstanding shares and convertible shares of “freestanding instruments”, such that the Company can reserve sufficient shares to settle “freestanding instruments.”
	During fiscal year 2013, the Company estimated the fair value of the embedded derivatives using a binomial option-pricing model with the following assumptions: conversion price of $0.75 per share according to the agreements; risk free interest rate of 0.10% to 0.11%; expected life of 0.83 to 1.00 years; expected dividends of zero; a volatility factor of 200% to 229%; and a stock price of $1.45.  The expected lives of the instruments are equal to the average term of the conversion option.  The expected volatility is based on the historical price volatility of the Company’s common stock.  The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.  The loss on derivative liabilities for the fiscal years 2013 and 2012 was $333,406 and $2,104,389, respectively.

14_Preferred_Stock

14. Preferred Stock	12 Months Ended
	Sep. 30, 2013
Notes	'
14. Preferred Stock	'
	14. Preferred Stock
	The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.00001 per share.  Pursuant to the Company’s Certificate of Incorporation, the Board of Directors has the authority to amend the Company’s Certificate of Incorporation, without further stockholder approval, to designate and determine the preferences, limitations and relative rights of the preferred stock before any issuance of the preferred stock and to create one or more series of preferred stock, fix the number of shares of each such series, and determine the preferences, limitations and relative rights of each series of preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, and liquidation preferences.
	Series C Convertible Preferred Stock
	On October 4, 2011, the Company issued 480,000 shares of Series C convertible preferred stock (“Series C preferred stock”) in connection with the patent license agreement settlement (see Note 6).  The par value of the Series C is $0.00001 per share.  The Series C preferred stock is non-voting stock.  Each share of Series C preferred stock may be converted into one share of common stock, provided, however, that a holder may not convert shares of Series C preferred stock which, upon conversion, would result in the holder becoming the beneficial owner of more than 4.99% of the issued and outstanding common stock of the Company.
	During fiscal year 2012, the Company amended the rights and preferences of the Series C preferred stock as follows:
	·         Required payment of dividends at a rate of 8% per annum in either cash or common stock at the Company’s discretion.  If paid in common stock, the price of the common stock is the average closing price of the last 10 trading days of each quarter; and
	·         Permitted conversion of the Series C preferred stock into common stock at any time after June 30, 2012.
	During fiscal year 2013, the Company issued 9,062 shares of Series D preferred stock for accrued dividends of $53,992 associated with Series C preferred stock.  During fiscal year 2012, the Company issued 10,218 shares of Series D preferred stock for accrued dividends of $35,763 associated with Series C preferred stock.
	Series D Convertible Preferred Stock
	On October 4, 2011, the Board of Directors designated 1,000,000 shares of preferred stock as Series D convertible preferred stock (“Series D preferred stock”).  As originally designated, the Series D preferred stock vested immediately upon issuance, and each share of Series D preferred stock was convertible into one share of common stock.  The original designation also provided that the Series D preferred stock was non-voting and would not receive dividends.  In addition, conversion of the Series D preferred stock was limited to not more than 4.99% of the issued and outstanding common stock.
	During fiscal year 2012, the Board of Directors approved the following amendments to the designation of the rights and preferences of the Series D preferred stock prior to the issuance of any of the shares:
	·         Changed the conversion ratio from  one share of common stock for one share of Series D preferred stock to  five shares of common stock for one share of Series D preferred stock;
	·         Added an annual dividend rate of 8%, payable in stock or cash quarterly beginning April 1, 2012;
	·         Changed the shares from non-voting to voting, on an as-converted basis;
	·         Eliminated the 4.99% conversion limitation;
	·         Permitted conversion of the Series D preferred stock, commencing April 1, 2012;
	·         Permitted the Company, at its option, to redeem the Series D preferred shares at a redemption price equal to 120% of the original purchase with 15 days notice.
	During fiscal year 2013, the Company issued the following shares of Series D preferred stock:
	·         103,843 shares for $817,482 in loan origination fees;
	·         71,800 shares for advisory services through December 2014, the value on the date of grant was $230,800;
	·         20,000 shares for consulting services through December 2013, the value on the date of grant was $60,000;
	·         52,913 shares for $150,000 in previously accrued Board of Directors’ fees and $61,652 of compensation for services;
	·         46,300 shares for a bonus to an officer for services, the value on the date of grant was $234,700;
	·         9,062 shares for dividends on Series C preferred stock, the value on the date of grant was $53,992;
	·         5,025 shares for dividends on Series D preferred stock, the value on the date of grant was $31,689;
	·         126,117 shares for consulting services by an entity controlled by an officer of the Company, which were previously accrued in the amount of $564,280;
	·         85,000 shares to an entity controlled by an officer of the Company for consulting services, the value on the date of grant was $455,000;
	·         80,000 shares for a bonus to the CEO of the Company for signing an employment agreement with the Company, the value at the date of grant was $320,000, which cannot convert to common stock until the Company has 20,000 members;
	·         2,055 shares for services with value of $14,899 on the date of grant.
	During fiscal year 2013, an employee of the Company converted 50,000 shares of Series D preferred stock into 250,000 shares of common stock.  The Company also accrued $232,834 of dividends on Series D preferred stock and settled the accrued dividends by issuing 5,025 shares of Series D preferred stock and 143,465 shares of common stock during fiscal year 2013.
	Series E Convertible Preferred Stock
	During fiscal year 2013, the Board of Directors designated shares of preferred stock as Series E convertible preferred stock (“Series E preferred stock”).  The Series E preferred stock vests immediately upon issuance. Series E preferred stock is convertible into common stock at $1.00 per share, the conversion price is adjustable if there are distributions of common stock or stock split by the Company.  The designation also provides that the Series E preferred stock would be non-voting and would receive a monthly dividend of 3.322% for 25 to 32 months.  In addition, the convertibility and the redemption price of the Series E preferred stock is gradually reduced by dividend payments over 25 to 32 months.  After the dividend payment term, the redemption price of Series E preferred stock is $0 and the Series E preferred stock has no convertibility to common stock.
	During fiscal year 2013, $614,765 of debenture loans and accrued interests converted into 61,723 shares of Series E preferred stock.  During fiscal year 2013, the Company paid dividends of $17,271 to Series E shareholders.  As of September 30, 2013, the redemption price for the Series E preferred stock was $601,585.
	Liquidation Preference
	Upon any liquidation, dissolution or winding up of the Company, before any distribution or payment may be made to the holders of the common stock, the holders of the Series C, Series D, and Series E preferred stock are entitled to be paid out of the assets an amount equal to $1.00 per share plus all accrued but unpaid dividends.  If the assets of the Company are insufficient to make payment in full to all holders of preferred stock, then the assets shall be distributed among the holders of preferred stock ratably in proportion to the full amounts to which they would otherwise be respectively entitled.

15_Common_Stock

15. Common Stock	12 Months Ended
	Sep. 30, 2013
Notes	'
15. Common Stock	'
	15. Common Stock
	During fiscal year 2013, the Company issued the following shares of common stock:
	·         327,382 shares valued at $458,929 as compensation for services to six independent consultants;
	·         220,000 shares valued at $318,000 as compensation for two key employees as an incentive to work for the Company.  The stock vests according to the terms of the employment agreements;
	·         27,650 shares for employee bonuses valued at the date of grant at $39,825;
	·         350,000 shares valued at $350,000 for option exercises from employee bonuses granted by the Company;
	·         150,000 shares valued at $187,500 for an employment contract extension with a key employee;
	·         25,000 shares valued at $31,750 to medical advisory board members for services through September 2014;
	·         25,000 shares valued at $31,750 for services provided by a board member;
	·         141,987 shares as loan origination fees at a value of $387,849;
	·         4,758 shares valued at $7,137 for the extension of related-party payables;
	·          40,000 shares valued at $61,500 for the extension of third-party notes payable;
	·         13,439,190 shares for the conversion of outstanding debt in the amount of $18,467,123;
	·         2,600 shares valued at $3,900 as part of the issuance of $26,000 of new debt to a related party;
	·         166,200 shares valued at $225,300 to settle an accrued liability of $126,200;
	·         250,000 shares for the conversion of 50,000 shares of Series D preferred stock;
	·         425,000 shares for the exercise of options held by two key managers of GWire;
	·         200,625 shares valued at $232,765 as dividends accrued for Series C and Series D preferred stock holders;
	·         1,313,334 shares valued at $1,842,334 for cash of $985,000;
	·         29,600 shares to employees in accordance with a restricted stock agreement:
	During fiscal year 2012, the Company issued the following shares of common stock:
	·         60,000 shares for settlement of a patent license agreement, with value on the date of grant of $240,000;
	·         129,161 shares for consulting services, with value on the date of grant of $218,906;
	·         60,000 shares for settlement of $312,000 of accrued liabilities;
	·         200,000 shares in connection with a settlement agreement.  During fiscal year 2010, the Company granted Class D warrants for the purchase of 158,416 shares of common stock and Class E warrants for the purchase of 41,584 shares of common stock.  During fiscal year 2012, the Company entered into a settlement agreement with the holders of these warrants to resolve claims of the holders regarding their conversion of shares of preferred stock.  Under the settlement agreement, the holders exchanged the Class D and Class E warrants for 200,000 shares of common stock and the warrants were cancelled.  The Company recognized $500,000 of expense due to the conversion;
	·         231,000 shares from conversion of related–party, short-term notes payable in the amount of $92,400; and
	·         100,000 shares for loan origination fees of $70,000.
	In June 2011, the Company entered into a service contract with a former CEO for services to be rendered from October 2010 through September 2014.  As part of this service contract, the Company issued 400,000 shares of restricted common stock with a fair value on the date of grant of $1,840,000, as payment for past and future services.  During fiscal year 2012, the Company accelerated the vesting of the shares and recognized the residual compensation expense of $1,380,000 related to the issuance of these shares.
	In fiscal year 2010, the Company awarded certain employees restricted stock totaling 67,900 shares, valued at $916,650, in connection with Company milestones.  In fiscal year 2013, the Company issued 29,600 restricted shares of common stock valued at $399,600, and reduced the shares of non-vested common stock by 25,700 shares due to the change of employment status of individuals.  In fiscal year 2012, no restricted shares of common stock were issued to employees.  During fiscal years 2013 and 2012, the Company recognized compensation expense of $0 and $168,419, respectively.  As of September 30, 2013 and 2012, the unrecognized stock-based compensation was $0 and $245,952, respectively, and will be recognized over the remaining vesting terms.

16_Stock_Options_and_Warrants

16. Stock Options and Warrants	12 Months Ended
	Sep. 30, 2013
Notes	'
16. Stock Options and Warrants	'
	16. Stock Options and Warrants
	The fair value of each stock option or warrant is estimated on the date of grant using a binomial option-pricing model.  The expected life of stock options or warrants represents the period of time that the stock options or warrants are expected to be outstanding, based on the simplified method.  Expected volatilities are based on historical volatility of the Company’s common stock, among other factors.  The Company uses the simplified method within the valuation model due to the Company’s short trading history.  The risk-free rate related to the expected term of the stock option or warrants is based on the U.S. Treasury yield curve in effect at the time of grant.  The dividend yield is zero.
	During fiscal years 2013 and 2012, the Company measured the fair value of the warrants using a binomial valuation model with the following assumptions:
		2013		2012
	Exercise price	$0.75 - $10.00		$0.40 - .44
	Expected term (years)	1.5 - 2.5		2.5
	Volatility	219% - 298%		131% - 135%
	Risk-free rate	0.23% - 0.88%		0.39% - 0.44%
	Dividend rate	0%		0%
	During fiscal year 2013, the Company recorded stock-based compensation expense relating to the following stock options and warrants:
	·         Options to purchase 433,333 shares were granted to each of three employees of 4G, 1,300,000 total shares, as part of their employment agreements dated June 21, 2012, with an exercise price of $1.00 per share. These options vest as described in Note 4. The options expire in June 2017. The value of the options at the date of grant was $1,147,163. The Company amortizes the expense based on expected completion dates of the milestones. During fiscal year 2013, the Company recognized $846,898 of the total compensation expense. As of September 30, 2013, options for 260,000 shares have vested.
	·         Options to purchase 1,000,000 shares were granted to the Company’s CEO for services as part of his employment agreement dated July 2012, with an exercise price of $1.00 per share. One tenth (100,000 shares) of the options vest for each milestone of 5,000 additional members added to the Company since the beginning of his employment in July 2012 until fully vested. The options expire in July 2017. The Company amortizes the expense based on expected completion dates of the milestones. During fiscal year 2013, the Company recognized $660,140 of the total compensation expense. As of September 30, 2013, options for 500,000 shares have vested due to the Company reaching certain milestones according to the contract. In August 2013, the CEO exercised options to purchase 350,000 shares of common stock at $1.00 per share.
	·         Options to purchase 212,500 shares were granted to both key managers of GWire, 425,000 in aggregate, with an exercise price of $1.00 per share. Under the option agreements, the only method of exercise requires the employee to submit up to 212,500 shares of GWire stock, awarded as part of the employment agreements dated November 1, 2012 to the Company in exchange for equivalent shares of the Company’s common stock, up to $425,000 in total. The options were fully vested upon issuance. In April 2013, both managers converted all of these options together with 4,250,000 shares of GWire stock into 425,000 shares of the Company’s common stock. As a result, the Company owns 100% of GWire as of June 30, 2013.
	·         Options to purchase 25,300 shares were granted to GWire employees, with an exercise price of $1.00 per share. The options vested immediately and the Company recognized $32,572 as compensation expense during fiscal year 2013.
	·         Options to purchase 100,000 shares were granted as part of an employment agreement signed with a new employee dated May 2013, with an exercise price of $1.65 per share. One quarter (25,000 shares) of the options vest after one year and the remaining balance vests equally over the following nine quarters (8,333 per quarter). The options expire in May 2018. During fiscal year 2013, the Company recognized $12,689 of compensation expense associated with the options.
	·         Options to purchase 100,000 shares were granted as part of a loan extension agreement with an unrelated party, with an exercise price of $1.00 per share. The options vested immediately and the Company recognized $103,495 of interest expense during fiscal year 2013.
	·         Options to purchase 100,000 shares were granted for consulting services rendered by a third party, with an exercise price of $1.00 per share. The options vested immediately and the Company recognized $134,785 of consulting expense during fiscal year 2013.
	·         Options to purchase 36,667 shares were granted as loan due diligence fees to an unrelated party, with an exercise price of $0.75 per share. The options vested immediately and the Company recorded $51,492 as loan discount, which is being amortized over the life of the loan.  During fiscal year 2013, the Company recognized $8,317 as interest expense for the loan discount amortization.
		Warrants 1	Warrants 2	Warrants 3	Warrants 4	Warrants 5	Warrants 6	Warrants 7	Warrants 8
	Warrants	1300000	1000000	425000	25300	100000	100000	100000	36667
	Exercise price	1	1	1	1	1.65	1	1	0.75
	Interest expense						103495		8317
	Consulting expense							134785
	Additional compensation expense	846898	660140		32572	12689
	The following table summarizes information about stock options and warrants outstanding as of September 30, 2013:
	Options and Warrants	Number of Options and Warrants		Weighted-Average Exercise Price
	Outstanding as of October 1, 2012	2,386,587		$              1.47
	Granted	2,086,967		1.04
	Exercised	(875,000)		1.00
	Forfeited	-		-
	Outstanding as of September 30, 2013	3,598,554		1.33
	Exercisable as of September 30, 2013	2,271,887		1.50
	As of September 30, 2013, the outstanding warrants have an aggregate intrinsic value of $434,890, and the weighted average remaining term of the warrants is 3.13 years.

17_Segment_Information

17. Segment Information	12 Months Ended
	Sep. 30, 2013
Notes	'
17. Segment Information	'
	17. Segment Information
	The Company operates two business segments based primarily on the nature of the Company’s products. The Chronic Illness Monitoring segment is engaged in the business of developing, distributing and marketing mobile monitoring of patient vital signs and physical activity to self-insured companies. The CareServices segment is engaged in the business of developing, distributing and marketing mobile health monitoring and concierge services to distributors and consumers. The Company previously operated a reagents business which was sold in June 2013.  The Company no longer holds any ownership interest in the reagents business.
	Additionally, at the corporate level, the Company raises capital and provides for the administrative operations of the Company as a whole.
	The following table reflects certain financial information relating to each reportable segment for fiscal years 2013 and 2012:
		Corporate	Chronic Illness Monitoring	CareServices	Reagents	Total
	Fiscal year ended September 30, 2013
	Sales to external customers	$                  -	$ 9,738,988	$    1,660,544	$     351,645	$ 11,751,177
	Segment loss	(21,986,526)	(460,017)	(3,179,151)	(5,312)	(25,631,006)
	Interest expense, net	5,583,932	-	-	-	5,583,932
	Segment assets	600,892	9,482,037	2,291,121	-	12,374,050
	Fixed assets and leased equipment purchases	243,273	-	241,527	888	485,688
	Depreciation and amortization	124,269	114,440	984,663	9,362	1,232,734
	Fiscal year ended September 30, 2012
	Sales to external customers	$                -	$   706,888	$       352,223	$ 467,259	$    1,526,370
	Segment loss	(11,298,372)	(532,207)	(389,187)	(145,990)	(12,365,756)
	Interest expense, net	858,224	-	-	-	858,224
	Segment assets	397,557	1,957,779	3,224,579	296,039	5,875,954
	Fixed assets and leased equipment purchases	93,315	-	257,857	-	351,172
	Depreciation and amortization	304,841	-	64,348	16,296	385,485

18_Income_Tax_Disclosure

18. Income Tax Disclosure	12 Months Ended
	Sep. 30, 2013
Notes	'
18. Income Tax Disclosure	'
	18. Income Taxes
	As of September 30, 2013, the Company had net operating loss carryforwards available to offset future taxable income, if any, of approximately $51,800,000, which will begin to expire in 2027.  The utilization of the net operating loss carryforwards is dependent upon the tax laws in effect at the time the net operating loss carryforwards can be utilized.  The Internal Revenue Code contains provisions that likely could reduce or limit the availability and utilization of these net operating loss carryforwards.  For example, limitations are imposed on the utilization of net operating loss carryforwards if certain ownership changes have taken place or will take place.  The Company will perform an analysis to determine whether any such limitations have occurred as the net operating losses are utilized.
	The amount and ultimate realization of the benefits from the net operating loss carryforwards are dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined.  The Company has established a valuation allowance against all deferred income tax assets not offset by deferred income tax liabilities due to the uncertainty of their realization.  Accordingly, there is no benefit for income taxes in the accompanying statements of operations.
	Deferred income taxes are determined based on the estimated future effects of differences between the consolidated financial reporting and income tax reporting bases of assets and liabilities given the provisions of currently enacted tax laws and the tax rates expected to be in place.  For fiscal years 2013 and 2012, the Company’s expected federal tax rate was 34%.
	The deferred income tax assets (liabilities) were comprised of the following as of September 30:
		2013	2012
	Net operating loss carryforwards	$ 19,330,000	$  11,807,000
	Depreciation, amortization and reserves	453,000	101,000
	Stock-based compensation	1,863,000	1,113,000
	Accrued vacation	2,000	20,000
	Valuation allowance	(21,648,000)	(13,041,000)
	Total	$                -	$                -
	Reconciliations between the benefit for income taxes at the federal statutory income tax rate and the Company’s benefit for income taxes for fiscal years 2013 and 2012 were as follows:
		2013	2012
	Federal income tax benefit at statutory rate	$       8,715,000	$         4,204,000
	State income tax benefit, net of federal income tax effect	846,000	408,000
	Non-deductible expenses	(954,000)	(804,000)
	Change in valuation allowance	(8,607,000)	(3,808,000)
	Benefit for income taxes	$                     -	$                      -
	During fiscal years 2013 and 2012, the Company recognized no interest or penalties, and there were no changes in unrecognized tax benefits from tax positions taken or from lapsed statutes of limitations.  There were no settlements with taxing authorities.  As of September 30, 2013, the Company had no unrecognized tax benefits that, if recognized, would affect the effective tax rate, and there are no positions that are anticipated to significantly increase or decrease.  The Company had no tax examinations beginning, ending, or remaining in process as of and for the years ended September 30, 2013 and 2012.  Tax returns for fiscal years subsequent to 2009 remain subject to examination.

19_Commitments_and_Contingenci

19. Commitments and Contingencies	12 Months Ended
	Sep. 30, 2013
Notes	'
19. Commitments and Contingencies	'
	19. Commitments and Contingencies
	The Company leases office space under non-cancelable operating leases.  Future minimum rental payments under non-cancelable operating leases as of September 30, 2013 were as follows:
	Years Ending September 30,
	2014	$            277,603
	2015	308,330
	2016	317,580
	2017	327,107
	2018	280,077
		$         1,510,697
	The Company’s rent expense for facilities held under non-cancelable operating leases for fiscal years 2013 and 2012 was approximately $268,000 and $204,000, respectively.
	In May 2013, the Company entered into a settlement agreement and patent license agreement and an agreed motion was filed to dismiss all claims of a lawsuit.  The final payment required by the settlement agreement and patent license patent agreement was made in December, 2013.

20_Subsequent_Events

20. Subsequent Events	12 Months Ended
	Sep. 30, 2013
Notes	'
20. Subsequent Events	'
	20. Subsequent Events
	Subsequent to September 30, 2013, the Company entered into the following agreements and transactions:
	(1)     In October 2013, the Company entered into a loan conversion agreement with an investor.  The Company issued 8,347 shares of Series E preferred stock for the conversion of a Series A debenture agreement representing principal and interest in the amount of $83,473.
	(2)     In November 2013, the Company entered into a loan conversion agreements with two investors.  The Company issued 441,735 shares of common stock for the conversion of a note payable representing principal and interest in the amount of $331,301.
	(3)     In December 2013, the Company designated 7,803 shares of preferred stock as Series F variable rate convertible preferred stock and completed the sale of $3,120,000 in 8% original issue shares of Series F preferred stock.  The Company received $2,835,771 cash after fees and expenses.   As part of the transaction consultants invested an additional $220,000 under subscription agreements to purchase 247 shares of Series F preferred stock.  In addition, the Company issued 3,495,000 warrants exercisable at $1.10 per share for five years as part of the overall transaction.
	(4)     In December 2013, the Company entered into a loan conversion agreement with one of its debt holders.  The Company issued 857 shares of Series F preferred stock for the conversion of a note payable representing principal and interest in the amount of $573,868.  In addition, the Company issued 856,977 warrants exercisable at $1.10 per share for five years.
	(5)     In December 2013, the Company entered into a loan conversion agreement with a related party.  The Company issued 1,883,675 shares of common stock for the conversion of a note payable representing principal and interest in the amount of $1,126,026.  In addition, the Company issued 410,348 warrants exercisable at $1.10 per share for five years.
	(6)     In December 2013, the Company entered into a loan conversion agreement with a related party.  The Company issued 1,100,110 shares of common stock for the conversion of a note payable representing principal and interest in the amount of $659,474.  In addition, the Company issued 239,652 warrants exercisable at $1.10 per share for five years.
	(7)     In December 2013, the Company entered into a loan conversion agreement with the Company’s chief executive officer.  The Company issued 213,334 shares of common stock for the conversion of a note payable representing principal and interest in the amount of $160,000.
	(8)     In December 2013, an investor converted 480,000 shares of Series C preferred stock to 672,000 shares of common stock.
	(9)     In December 2013, related party and non-related party investors converted 893,218 shares of Series D preferred stock to 6,252,526 shares of common stock.
	(10) In December 2013, the Company entered into a loan conversion agreement with one of its debt holders.  The Company issued 66,667 shares of common stock for the conversion of a note payable representing principal and interest in the amount of $50,000.
		Event 1	Event 2	Event 3	Event 4	Event 5	Event 6	Event 7	Event 8	Event 9	Event 10
	Conversion of Series A Debenture-Shares	8347
	Conversion of Note Payable -Shares		441735		857	1883675	1100110	213334			66667
	Principal and Interest Balance	83473	331301		573868	1126026	659474	160000			50000
	Preferred Stock Designated As Series F Variable Rate Convertible Preferred Stock			7803
	Proceeds From Sale of Series F Preferred Stock			2835771
	Warrants Issued			3495000		410348	239652
	Series C Preferred Stock converted to Common Stock								480000
	Series D Preferred Stock converted to Common Stock									893218
	Preferred Stock converted to Common Stock								672000	6252526

1_Organization_and_Nature_of_O1

1. Organization and Nature of Operations: Going Concern (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Going Concern	'
	Going Concern
	Although the Company had positive gross margin for fiscal year 2013, it has incurred negative cash flows from operating activities, recurring net losses, negative working capital, and negative total equity.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	In order for the Company to remove substantial doubt about its ability to continue as a going concern, it must improve gross margins, generate positive cash flows from operating activities, and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management’s plans with respect to this uncertainty include raising additional capital by issuing equity securities and increasing the sales of the Company’s services and products.  Subsequent to year end, the Company (1) completed the sale of $3,120,000 of 8% Series F variable rate convertible preferred stock (“Series F preferred stock”); (2) converted $2,301,801 of debt and accrued interest to common stock; and (3) converted $573,886 of debt and accrued interest to Series F variable rate convertible preferred stock (see Note 20). There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to offset operating losses.  If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and may have to cease operations.

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Use of Estimates in The Preparation of Financial Statements	'
	Use of Estimates in the Preparation of Financial Statements
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.
	In May 2013, the Company effected a 10-for-1 reverse common stock split.  The consolidated financial statements and notes for all periods presented have been retroactively adjusted to reflect the reverse common stock split.

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies: Discontinued Operations, Policy (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Discontinued Operations, Policy	'
	Discontinued Operations
	In June 2013, the Company sold the net assets and operations of its reagents business segment to a third party for $184,318 in cash.  During fiscal years 2013 and 2012, the Company recognized a loss from discontinued operations of $5,312 and $145,990, respectively.

2_Summary_of_Significant_Accou3

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying values of cash, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature and liquidity of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. Based on current market condition, the Company estimates the fair values of its long-term debt obligations approximate their carrying values as of September 30, 2013.

2_Summary_of_Significant_Accou4

2. Summary of Significant Accounting Policies: Concentrations of Credit Risk (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	The Company has cash in bank accounts that, at times, may exceed federally insured limits.  The Company has not experienced any losses in these accounts.
	In the normal course of business, the Company provides credit terms to its customers and requires no collateral.  The Company performs ongoing credit evaluations of its customers’ financial condition.  The Company maintains an allowance for doubtful accounts receivable based upon management’s specific review and assessment of each account at the period end.
	During fiscal year 2013, the Company had revenues from three significant Chronic Illness Monitoring customers, which represented 72% of total revenue.  As of September 30, 2013, accounts receivable from significant customers represented 92% of total accounts receivable.  During fiscal year 2012, the Company had revenues from one significant Chronic Illness Monitoring customers, which represented 28% of total revenues.  As of September 30, 2012, accounts receivable from significant customers represented 51% of total accounts receivable.

2_Summary_of_Significant_Accou5

2. Summary of Significant Accounting Policies: Accounts Receivable (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts.  Specific reserves are estimated by management based on certain assumptions and variables, including the customer’s financial condition, age of the customer’s receivables and changes in payment histories.  Accounts receivable are written off when management determines the likelihood of collection is remote.  A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date.  Interest is not charged on accounts receivable that are past due.  The Company recorded an allowance for doubtful accounts of $76,544 and $20,195 as of September 30, 2013 and 2012, respectively.

2_Summary_of_Significant_Accou6

2. Summary of Significant Accounting Policies: Inventories (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Inventories	'
	Inventories
	Inventories are recorded at the lower of cost or market, cost being determined using the first-in, first-out (“FIFO”) method. Chronic Illness Monitoring inventory consists of diabetic supplies.  The Company writes down inventory for obsolescence and excessive levels to estimated net realizable value.  Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term.  Inventories consist of the following as of September 30:
					2013		2012
	Chronic Illness Monitoring
		Finished goods		$	1,249,220	$	185,884
	Careservices
		ActiveHomeTM			-		56,767
	Reagents
		Raw materials			-		36,211
		Work in process			-		5,745
		Finished goods			-		6,161
			Total inventories	$	1,249,220	$	290,768

2_Summary_of_Significant_Accou7

2. Summary of Significant Accounting Policies: Property, Plant and Equipment, Policy (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Property, Plant and Equipment, Policy	'
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization.  Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years.  Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease.  Expenditures for maintenance and repairs are expensed as incurred.  Upon the sale or disposal of property and equipment, any gains or losses are included in the results of operations.

2_Summary_of_Significant_Accou8

2. Summary of Significant Accounting Policies: Goodwill (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Goodwill	'
	Goodwill
	Goodwill is not amortized but is reviewed for potential impairment at least annually.  The identification and measurement of goodwill impairment involves the estimation of the fair value of the Company’s reporting units.  The estimates of fair value of reporting units are based on the best information available as of the date of the assessment and incorporate management assumptions about expected future cash flows.  Future cash flows can be affected by changes in Company performance, industry or market conditions, or overall economic trends.  Management determined goodwill that was not impaired during fiscal years 2013 or 2012.

2_Summary_of_Significant_Accou9

2. Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Impairment of Long-lived Assets	'
	Impairment of Long-Lived Assets
	Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets, which range from 2 to 20 years.  Long-lived assets, including intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.  Management determined that long-lived assets were not impaired during fiscal years 2013 or 2012.

Recovered_Sheet1

2. Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Revenue Recognition	'
	Revenue Recognition
	The Company’s revenue has historically been from three sources: (i) sales from Chronic Illness Monitoring services and supplies; (ii) sales from CareServices; and (iii) sales of medical diagnostic stains from the reagents segment, which was sold during fiscal year 2013 and reported as discontinued operations.
	Chronic Illness Monitoring
	The Company began chronic illness monitoring sales as a result of its acquisition of 4G Biometrics, LLC in the quarter ended March 31, 2012 (see Note 4).  The Company recognizes Chronic Illness Monitoring revenue when persuasive evidence of an arrangement with the customer exists, title passes to the customer, prices are fixed or determinable, and collection is reasonably assured.
	Shipping and handling billed to customers are included in revenues.  The related freight costs and supplies directly associated with shipping products to customers are included as a component of cost of revenues.  Sales of Chronic Illness Monitoring products and services do not contain multiple deliverables.
	The Company enters into agreements with insurance companies, disease management companies, and self-insured companies (collectively, customers) to lower medical expenses by distributing diabetic testing supplies to their customers or employees (members) and monitoring their test results.  Customers are obligated to pay for the supplies at the time of shipment and cash is due from these customers as the product is deployed to the members.  The terms of these contracts are generally one year and, unless terminated by either party, will automatically renew for another year.  Collection terms are net 30-days after claims are submitted.
	Revenue is recognized on the date of sale because the following exist:
	·         The price to the contracted customer is fixed or determinable at the date of sale.
	·         The customer has paid or is obligated to pay the Company within terms.
	·         The customer’s obligation to the Company is not changed in the event of theft or physical destruction or damage of the product.
	·         Once the product is shipped, there is no right of return.
	CareServices
	The “CareServices” segment sells devices to distributors as well as provides monitoring services to end users on a contractual basis.  The Company typically enters into contracts on a month-to-month basis with customers (members) that use the Company’s CareServices.  However, either party may cancel these contracts at any time with 30-days notice.  Under the Company’s standard contract, the device becomes billable on the date the member orders the product, and remains billable until the device is returned to the Company.  The Company recognizes revenue on devices at the end of each month that CareServices have been provided.  In those circumstances in which the Company receives payment in advance, the Company records these payments as deferred revenue.
	The Company recognizes CareServices revenue when persuasive evidence of an arrangement with the customer exists, title passes to the customer, prices are fixed or determinable, and collection is reasonably assured.  Shipping and handling fees billed to the customer are included in revenues.  The related freight costs and supplies directly associated with shipping products to members are included as a component of cost of revenues.  All CareServices sales are made with net 30-day payment terms.
	Revenue is recognized on the date of sale because the following exist:
	·         The price to the customer is fixed or determinable at the date of sale.
	·         The customer has paid or is obligated to pay within terms, and the obligation is not contingent on resale of the product.
	·         The customer’s obligation is not changed in the event of theft or physical destruction or damage of the product.
	·         The customer acquiring the product for resale has economic substance apart from the Company.
	·         The Company does not have significant obligations for future performance to bring about resale of the product by the customer.
	·         The amount of future returns are estimatable and are not significant.
	The vast majority of CareServices revenues are for services.  Because equipment sales are not material, the Company presents services and equipment sales together in the accompanying financial statements.
	The Company’s distributors are not required to maintain specified amounts of product on hand, and distributors are not required to make minimum purchases to maintain distributor status.  Distributors have no stock rotation rights or additional rights of return.  Revenues from products sold with long-term service contracts are recognized ratably over the expected life of the contract.  Revenues are recorded net of estimated returns and discounts.
	Reagents
	Prior to the sale of the reagent segment, the Company recognized reagents revenues when persuasive evidence of an arrangement with the customer existed, title passed to the customer, prices were fixed or determinable, and collection was reasonably assured.  Prior to the sale of the reagent segment, shipping and handling fees billed to customers were included in revenues and the related freight costs and supplies directly associated with shipping products to customers were included as a component of cost of revenues.

Recovered_Sheet2

2. Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Research and Development Costs	'
	Research and Development Costs
	All expenditures for research and development are charged to expense as incurred. Research and development expenses for fiscal years 2013 and 2012 were $832,271 and $187,230, respectively. The expenditures for fiscal year 2013 were primarily for the development of the Chronic Illness Monitoring operating system. The expenditures for fiscal year 2012 were for software development efforts for the chronic illness market.

Recovered_Sheet3

2. Summary of Significant Accounting Policies: Advertising Costs (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Advertising Costs	'
	Advertising Costs
	The Company expenses advertising costs as incurred.  Advertising expenses for fiscal years 2013 and 2012 were $59,330 and $176,300, respectively.  Advertising expenses primarily relate to the Company’s Chronic Illness Monitoring segment.

Recovered_Sheet4

2. Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Income Taxes	'
	Income Taxes
	The Company recognizes deferred income tax assets or liabilities for the expected future tax consequences of events that have been recognized in the financial statements or income tax returns. Deferred income tax assets or liabilities are determined based upon the difference between the financial reporting bases and tax reporting bases of assets and liabilities using enacted tax rates expected to apply when the differences are expected to be settled or realized.  Deferred income tax assets are reviewed periodically for recoverability and valuation allowances are provided as necessary.  As of September 30, 2013, management has determined to provide a 100% allowance against deferred income tax assets as it is more likely than not these assets will not be realized.  Interest and penalties related to income tax liabilities, when incurred, are classified in interest expense and income tax provision, respectively.

Recovered_Sheet5

2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Stock-based Compensation	'
	Stock-Based Compensation
	The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.  That cost is recognized in the statement of operations over the period during which the employee is required to provide service in exchange for the award – the requisite service period.  The grant-date fair values of the equity instruments are estimated using option-pricing models adjusted for the unique characteristics of those instruments.

Recovered_Sheet6

2. Summary of Significant Accounting Policies: Net Loss Per Common Share (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the year.
	Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss available to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive common share equivalents then outstanding.  The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect.
	Common share equivalents consist of shares issuable upon the exercise of common stock warrants, shares issuable from restricted stock grants, shares issuable from convertible notes and convertible Series C, Series D and Series E preferred stock.  As of September 30, 2013 and 2012, there were 13,127,396 and 8,202,219 outstanding common share equivalents, respectively, that were not included in the computation of Diluted EPS as their effect would be anti-dilutive.  The common stock equivalents outstanding consist of the following as of September 30:
			2013	2012
	Common stock options and warrants		3,598,554	2,386,587
	Series C convertible preferred stock		480,000	480,000
	Series D convertible preferred stock		4,691,090	1,830,515
	Series E convertible preferred stock		601,585	-
	Convertible debt		3,738,917	3,444,217
	Restricted shares of common stock		17,250	60,900
		Total common stock equivalents	13,127,396	8,202,219

Recovered_Sheet7

2. Summary of Significant Accounting Policies: Reclassifications (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Reclassifications	'
	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year’s presentation.  The reclassification had no effect on the previously reported net loss.

Recovered_Sheet8

2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Sep. 30, 2013
Policies	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and has concluded that the future adoption of any such pronouncements will not have a material impact on the Company’s financial position, results of operations, or liquidity.

Recovered_Sheet9

2. Summary of Significant Accounting Policies: Inventories: Schedule of Utility Inventory (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Utility Inventory	'
					2013		2012
	Chronic Illness Monitoring
		Finished goods		$	1,249,220	$	185,884
	Careservices
		ActiveHomeTM			-		56,767
	Reagents
		Raw materials			-		36,211
		Work in process			-		5,745
		Finished goods			-		6,161
			Total inventories	$	1,249,220	$	290,768

Recovered_Sheet10

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of common stock equivalents (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of common stock equivalents	'
			2013	2012
	Common stock options and warrants		3,598,554	2,386,587
	Series C convertible preferred stock		480,000	480,000
	Series D convertible preferred stock		4,691,090	1,830,515
	Series E convertible preferred stock		601,585	-
	Convertible debt		3,738,917	3,444,217
	Restricted shares of common stock		17,250	60,900
		Total common stock equivalents	13,127,396	8,202,219

3_Discontinued_Operations_Sche

3. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	'
			2013		2012
	Revenues	$	351,645	$	467,259
	Cost of revenues		(300,396)		(392,049)
	Gross margin		51,249		75,210
	Selling, general and administrative expenses		(111,657)		(221,200)
	Loss from discontinued operations		(60,408)		(145,990)
	Gain on sale discontinued operations		55,096		-
	Net loss from discontinued operations	$	(5,312)	$	(145,990)

5_Property_Plant_and_Equipment1

5. Property, Plant and Equipment Disclosure: Schedule of Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Property and Equipment	'
				2013		2012
	Equipment		$	255,339	$	374,229
	Leasehold improvements			145,147		402,016
	Software			87,361		65,111
	Furniture			32,855		50,123
		Total gross property and equipment		520,702		891,479
	Accumulated depreciation and amortization			(223,972)		(625,401)
		Property and equipment, net	$	296,730	$	266,078

6_Patent_License_Agreement_Sch

6. Patent License Agreement: Schedule of Expected Amortization Expense (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Expected Amortization Expense	'
	Years Ending September 30,
	2014	$	126,870
	2015		126,870
	2016		126,870
	2017		126,870
	2018		59,440
		$	566,920

7_Customer_Contracts_Schedule_

7. Customer Contracts: Schedule of Future Customer Contract Amortization (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Future Customer Contract Amortization	'
	Years Ending September 30,
	2014	$	775,812
	2015		658,709
		$	1,434,521

8_Equipment_Leased_to_Customer1

8. Equipment Leased to Customers: Schedule of leased equipment (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of leased equipment	'
			2013		2012
	Leased equipment	$	389,492	$	457,898
	Accumulated depreciation		(115,862)		(144,905)
	Leased equipment, net	$	273,630	$	312,993

9_Notes_Payable_Schedule_of_De

9. Notes Payable: Schedule of Debt (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Debt	'
		2013	2012
	Note payable to the former owners of Green Wire, secured by customer contracts, imputed interest rate of 12%, with monthly installments over a 38-month term.  In March 2013, the Company issued 15,000 shares of common stock to extend two past due payments without penalty and the grant date fair value was $24,000, which will be amortized over the remaining life of the note.	$         1,766,971	$         2,236,737
	Notes payable with interest at 12%, secured by the Company's assets, due August 2014 and convertible into the shares of common stock at $0.75 per share.  The notes required $51,250 in due diligence and legal fees.  The Company issued warrants to purchase 36,667 shares of common stock as due diligence fees with a grant date fair value of $51,452.  The Company issued 25,000 shares of common stock with a grant date fair value of $31,250 to a related party as consideration for signing a personal guarantee.  The notes and accrued interest were converted to Series F preferred stock subsequent to September 30, 2013 (see note 20).	550,000	-
	Unsecured note with interest at 12%, due March 2013.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	250,000	250,000
	Unsecured notes with interest at 15% (18% after due date), due March and April 2013, respectively.  The Company issued 20,000 shares of Series D preferred stock as loan origination fees with a grant date fair value of $195,000.   Principal of $50,000 was converted to common stock subsequent to September 30, 2013 (see note 20).	185,476	-
	Series A debenture loans payable, secured by customer contracts and payable in 36 monthly installments, original due dates between September and April 2016. The loans bear interest at 12% and are convertible into common stock after 180 days.  After payment of principal and interest, the holders of the Series A and Series B debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out each lender's royalty by paying the respective lender $20,000 for every $25,000 loaned.  The note included a beneficial conversion feature valued at $901,000 at inception, which the Company is amortizing over the life of the loan.  The feature had an unamortized value of $47,934 as of September 30, 2013.  The majority of loans were converted during fiscal year 2013.   The remaining balance was converted to Series E preferred stock subsequent to September 30, 2013 (see note 20).	85,719	300,000
	Unsecured note with interest at 15%, due March 2013, currently in default. Note included a $25,000 cash and 100,000 shares of common stock as loan origination fees with a grant date fair value of $70,000.   The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	25,000	275,000
	Unsecured note with interest at 15% (18% after due date), due November 2012.  The Company issued 60,000 shares of Series D stock as loan origination fees with a grant date fair value of $150,000.  The note was guaranteed by the Company’s Chief Executive Officer.	-	1,500,000
	Total before discount and current portion	2,863,166	4,561,737
	Less discount	(528,663)	(187,587)
	Total notes payable	2,334,503	4,374,150
	Less current portion	(1,278,585)	(2,569,221)
	Total notes payable, net of current portion	$         1,055,918	$         1,804,929

9_Notes_Payable_Schedule_of_pr

9. Notes Payable: Schedule of principal payments on notes payable (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of principal payments on notes payable	'
	Years Ending September 30,
	2014	$	1,768,820
	2015		854,522
	2016		239,824
		$	2,863,166

10_Relatedparty_Notes_Payable_

10. Related-party Notes Payable: Schedule of related party notes payable (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of related party notes payable	'
		2013	2012
	Unsecured notes payable to an entity controlled by an officer of the Company with interest at 15% (18% in the event of default), due September 30, 2013.  The Company issued 60,000 shares of common stock as loan origination fees with a grant date fair value of $93,000.  The notes and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	$            600,000	$                     -
	Unsecured note payable to an entity controlled by an officer of the Company, with interest at 3% (18% in the event of default), due July 2013.  In July the lender agreed to extend the maturity date to September 30, 2013 with an interest at 12% (18% in the event of default).  The Company issued 30,000 shares of common stock with grant date fair value of $38,100 as loan origination fees.  In the event of default, the note is convertible into share of common stock at $0.75 per share. The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	300,000	-
	Unsecured note payable to an entity controlled by an officer of the Company, interest at 12% (18% in the event of default), due September 30, 2013.  The Company issued 30,000 shares of common stock with a grant date fair value of $37,500 as loan origination fees.  In the event of default, the note is convertible into shares of common stock at $0.75 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	300,000	-
	Unsecured notes payable to an entity controlled by an officer of the Company, interest at 12% (18% in the event of default), due April 2013.  In the event of default, the note is convertible into shares of common stock at $0.40 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	200,000	-
	Unsecured note payable to a lender under the control of the Company’s CEO, interest at 12%, due upon demand. The note is convertible into shares of common stock at $0.75 per share.  The Company recognized $148,750 in connection with the beneficial conversion feature.  The Company issued 17,500 shares of common stock with a grant date fair value of $26,250 as loan origination fees.  Subsequent to September 30, 2013 $160,000 of the note was converted to common stock (see note 20).	175,000	-
	Unsecured note payable with zero interest to an entity controlled by an officer of the Company.  The note was repaid in full subsequent to September 30, 2013.	150,000	-
	Unsecured note payable to an entity controlled by an officer of the Company, with interest at 12%, due August 2012.   During fiscal year 2013, the lender agreed to extend the maturity date to June 30, 2013 with an interest at 18% and 5,600 shares of Series D with a grant date fair value of $56,252 paid as a loan origination fee.  The note is currently in default.  The note also included $7,500 of loan origination fees added to the principal. In the event of default, the note is convertible into shares common stock at $0.40 per share.  The note and accrued interest was converted to common stock subsequent to September 30, 2013 (see note 20).	82,500	543,278
	Unsecured note payable to an officer of the Company with interest at 15%, due June 2012, currently in default.  The note includes $3,000 of loan origination fees added to the principal and is convertible into common stock at $0.50 per share.	33,000	33,000
	Unsecured note payable to an officer of the Company with interest at 12%, due September 30, 2013, currently in default.  The loan is convertible into the Company's common stock at a rate of $0.75 per share.  The Company recognized $22,820 in connection with the beneficial conversion feature.	26,721	-
	Unsecured note payable to an officer of the Company with interest at 12%, due upon demand.	13,644	-
	Unsecured notes payable with zero interest to an individual related to an officer of the Company.  The loan was repaid in full subsequent to September 30, 2013.	10,000	-
	Series B unsecured debenture loans from entities controlled by an officer of the Company, including $68,914 in loan origination fees added to the principal of the loans, payable in 36 monthly installments, maturing December 2015 and January 2016.  Of the debenture, $554,556 was issued to settle a related-party note payable with a total outstanding balance of $460,778 and $43,364 of related accrued interest.  Of the loan, $35,000 was issued to settle an accrued service fee.  The loans bear interest at 12% and are convertible into common stock after 180 days. After payment of principal and interest, the holders of the Series B and Series A debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out the royalty by paying the lender $22,000 for every $25,000 loaned.  During the fiscal year ended September 30, 2013, the Company issued 34,400 shares of Series D with a fair market value of $343,748 at date of grant as additional loan origination fees, and paid $30,102 of the loan principal.  The Company is late on certain monthly payments.  The notes include beneficial conversion features valued at $167,000 at inception, which the Company is amortizing over the life of the loan.  The feature had an unamortized value of $3,348 as of September 30, 2013.  During fiscal year 2013, $722,684 of outstanding principal and $49,895 of accrued interest were converted into 1,030,107 common shares at a rate of $0.75 per share.  The Company recorded $535,656 of expense associated with the induced conversion of these debenture loans. The majority of loans were converted during fiscal year 2013.  The remaining note of $5,270 and accrued interest were converted to common stock subsequent to September 30, 2013 (see note 20)	5,270	-
	Unsecured notes payable to a lender under the control of the Company’s CEO with a line of credit borrowing capacity of $2,000,000, interest at 12%, due July 2013. The notes were convertible into shares of common stock at $5.00 per share.  In connection with the notes payable, the Company issued 80,000 shares of Series D preferred stock (valued at $240,000).  The Company granted warrants to purchase 341,000 shares of common stock as a loan origination fee. These warrants vested immediately and are exercisable at $4.40 per share through November 3, 2016. The fair value of the warrants was $107,130, and was measured using a binomial valuation model with the following assumptions: exercise price $4.40; risk-free interest rate of .39%; expected life of 2.5 years; expected dividends of zero; a volatility factor of 134.57%; and market price on date of grant of $4.40.  During fiscal year 2012, the Company re-priced the exercise price of the warrants from $4.40 to $1.00 per share.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the lender in satisfaction of the outstanding balance of $620,687 plus $21,585 of accrued interest.  Upon the conversion of the note, the Company immediately recognized the unamortized debt discount of $209,143.	-	620,687
	Note payable to an entity controlled by an officer of the Company, interest at 12%, due December 2012.  This note was secured by real estate.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $300,000 plus $14,992 of accrued interest.	-	300,000
	Series A debenture loans from a former CEO and Chairman of the Company, secured by customer contracts, payable in 36 monthly installments, maturing September and December 2015.  The loans bear interest at 12% and are convertible into common stock after 180 days. After payment of principal and interest, the holders of the Series B and Series A debentures, as a class, are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company’s gross profits payable for the two-year period commencing at the maturity date; provided that no royalties are payable following conversion of any Series A or Series B debenture to the holder thereof.  The Company has the right to buy out each royalty by paying the lender $20,000 for every $25,000 loaned.  During fiscal year 2013, the Company paid $41,682 of the loan principal.  During fiscal year 2013, $342,912 of principal and interest were converted into 457,216 common shares.  The Company recorded $297,191 of expense associated with the induced conversion of these notes.	-	244,196
	Unsecured note payable to an entity controlled by an officer of the Company, including a $7,500 loan origination fee, interest at 12%, due August 2012.  The note was convertible into common stock at 50% of fair market value or $0.40 per share, whichever is less.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $82,500 plus $3,716 of accrued interest.	-	82,500
	Unsecured note payable to an entity controlled by an officer of the Company, including a $7,500 loan origination fee, interest at 12%, due September 2012. The note was convertible into common stock at $0.40 per share or 50% of market value, whichever was less.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $82,500 plus $3,173 of accrued interest.	-	82,500
	Notes payable to an entity controlled by an officer of the Company, including a $26,000 loan origination fee which was convertible into Series D preferred stock at any time at $2.00 per share, interest at 15%, due December 2012.  This note was secured by real estate.  During the three months ended December 31, 2012, the Company issued a Series A debenture payable to the entity in satisfaction of the outstanding balance of $51,000 plus $3,186 of accrued interest.  Upon the conversion of the note, the Company immediately recognized the unamortized debt discount of $14,238.	-	51,000
	Total before discount and current portion	1,896,135	1,957,161
	Less discount	(3,720)	(223,381)
	Total notes payable, related-party	1,892,415	1,733,780
	Less current portion	(1,892,415)	(1,563,923)
	Total  notes payable, related-party, net of current portion	$                     -	$            169,857

16_Stock_Options_and_Warrants_

16. Stock Options and Warrants: Schedule of fair value assumptions (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of fair value assumptions	'
		2013	2012
	Exercise price	$0.75 - $10.00	$0.40 - .44
	Expected term (years)	1.5 - 2.5	2.5
	Volatility	219% - 298%	131% - 135%
	Risk-free rate	0.23% - 0.88%	0.39% - 0.44%
	Dividend rate	0%	0%

16_Stock_Options_and_Warrants_1

16. Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Share-based Compensation, Activity	'
	Options and Warrants	Number of Options and Warrants	Weighted-Average Exercise Price
	Outstanding as of October 1, 2012	2,386,587	$              1.47
	Granted	2,086,967	1.04
	Exercised	(875,000)	1.00
	Forfeited	-	-
	Outstanding as of September 30, 2013	3,598,554	1.33
	Exercisable as of September 30, 2013	2,271,887	1.50

17_Segment_Information_Schedul

17. Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Segment Reporting Information, by Segment	'
		Corporate	Chronic Illness Monitoring	CareServices	Reagents	Total
	Fiscal year ended September 30, 2013
	Sales to external customers	$                  -	$ 9,738,988	$    1,660,544	$     351,645	$ 11,751,177
	Segment loss	(21,986,526)	(460,017)	(3,179,151)	(5,312)	(25,631,006)
	Interest expense, net	5,583,932	-	-	-	5,583,932
	Segment assets	600,892	9,482,037	2,291,121	-	12,374,050
	Fixed assets and leased equipment purchases	243,273	-	241,527	888	485,688
	Depreciation and amortization	124,269	114,440	984,663	9,362	1,232,734
	Fiscal year ended September 30, 2012
	Sales to external customers	$                -	$   706,888	$       352,223	$ 467,259	$    1,526,370
	Segment loss	(11,298,372)	(532,207)	(389,187)	(145,990)	(12,365,756)
	Interest expense, net	858,224	-	-	-	858,224
	Segment assets	397,557	1,957,779	3,224,579	296,039	5,875,954
	Fixed assets and leased equipment purchases	93,315	-	257,857	-	351,172
	Depreciation and amortization	304,841	-	64,348	16,296	385,485

18_Income_Tax_Disclosure_Sched

18. Income Tax Disclosure: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Deferred Tax Assets and Liabilities	'
		2013	2012
	Net operating loss carryforwards	$ 19,330,000	$  11,807,000
	Depreciation, amortization and reserves	453,000	101,000
	Stock-based compensation	1,863,000	1,113,000
	Accrued vacation	2,000	20,000
	Valuation allowance	(21,648,000)	(13,041,000)
	Total	$                -	$                -

18_Income_Tax_Disclosure_Sched1

18. Income Tax Disclosure: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Components of Income Tax Expense (Benefit)	'
		2013	2012
	Federal income tax benefit at statutory rate	$       8,715,000	$         4,204,000
	State income tax benefit, net of federal income tax effect	846,000	408,000
	Non-deductible expenses	(954,000)	(804,000)
	Change in valuation allowance	(8,607,000)	(3,808,000)
	Benefit for income taxes	$                     -	$                      -

19_Commitments_and_Contingenci1

19. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)	12 Months Ended
	Sep. 30, 2013
Tables/Schedules	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Years Ending September 30,
	2014	$            277,603
	2015	308,330
	2016	317,580
	2017	327,107
	2018	280,077
		$         1,510,697

Recovered_Sheet11

2. Summary of Significant Accounting Policies: Discontinued Operations, Policy (Details) (USD $)	1 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
Details	'	'	'
Proceeds from Sales of Business, Affiliate and Productive Assets	$184,318	'	'
Loss from discontinued operations	'	$5,312	$145,990

Recovered_Sheet12

2. Summary of Significant Accounting Policies: Accounts Receivable (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Allowance for Doubtful Accounts Receivable	$76,544	$20,195

Recovered_Sheet13

2. Summary of Significant Accounting Policies: Inventories: Schedule of Utility Inventory (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Inventory	$1,249,220	$290,768
Chronic Illness Monitoring	'	'
Inventory, Finished Goods, Gross	1,249,220	185,884
CareServices	'	'
ActiveHome	'	56,767
Reagents	'	'
Inventory, Finished Goods, Gross	'	6,161
Inventory, Raw Materials, Gross	'	36,211
Inventory, Finished Goods and Work in Process, Gross	'	$5,745

Recovered_Sheet14

2. Summary of Significant Accounting Policies: Research and Development Costs (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Research and development	$832,271	$187,230

Recovered_Sheet15

2. Summary of Significant Accounting Policies: Advertising Costs (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Advertising Expense	$59,330	$176,300

Recovered_Sheet16

2. Summary of Significant Accounting Policies: Net Loss Per Common Share (Details)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13,127,396	8,202,219

Recovered_Sheet17

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of common stock equivalents (Details)	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Common stock options and warrants	3,598,554	2,386,587
Series C convertible preferred stock	480,000	480,000
Series D convertible preferred stock	4,691,090	1,830,515
Series E convertible preferred stock	601,585	'
Convertible debt - Shares	3,738,917	3,444,217
Restricted shares of common stock	17,250	60,900
Total common stock equivalents	13,127,396	8,202,219

3_Discontinued_Operations_Sche1

3. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Gross profit (deficit)	$1,764,307	($214,199)
Selling, general and administrative (including $2,159,828 and $3,927,214, respectively, of stock-based compensation)	11,039,645	8,855,724
Loss from discontinued operations	-5,312	-145,990
Segment, Discontinued Operations	'	'
Revenues	351,645	467,259
Cost of Revenue	-300,396	-392,049
Gross profit (deficit)	51,249	75,210
Selling, general and administrative (including $2,159,828 and $3,927,214, respectively, of stock-based compensation)	-111,657	-221,200
Discontinued Operation, Amount of Other Income (Loss) from Disposition of Discontinued Operation, Net of Tax	-60,408	-145,990
Gain (Loss) on Sale of Other Assets	55,096	'
Loss from discontinued operations	($5,312)	($145,990)

4_Acquisitions_Details

4. Acquisitions (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2012	Sep. 30, 2013	Mar. 08, 2012	Sep. 01, 2012
		4G Biometrics, LLC	4G Biometrics, LLC	4G Biometrics, LLC	GWire
Business Acquisition, Cost of Acquired Entity, Cash Paid	'	'	'	$350,000	'
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred	'	'	'	50,000	'
Business Acquisition Equity Interests Issued Or Issuable Number Of Series D Convertible Shares Issued	'	'	'	160,000	20,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	'	433,333	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1.50	'	'	$1	'
Vested Common Stock Options	'	'	260,000	'	'
Business Acquisition, Cost of Acquired Entity, Purchase Price	'	'	'	1,040,000	2,276,737
Business Acquisition, Purchase Price Allocation, Goodwill Amount	'	'	'	825,894	'
Business Acquisition, Purchase Price Allocation, Other Assets	'	'	'	214,106	2,155,776
Business Acquisition, Cost of Acquired Entity, Other Noncash Consideration	'	'	'	'	2,236,737
Business Acquisition Equity Interests Issued Or Issuable Number Of Series D Convertible Shares Issued Value	'	'	'	'	40,000
Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents	'	'	'	'	12,215
Business Acquisition, Purchase Price Allocation, Current Assets, Receivables	'	'	'	'	13,976
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment	'	'	'	'	92,022
Business Acquisition, Purchase Price Allocation, Current Assets	'	'	'	'	16,964
Business Acquisition, Purchase Price Allocation, Equipment	'	'	'	'	229,249
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable	'	'	'	'	154,206
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities	'	'	'	'	55,117
Business Acquisition, Purchase Price Allocation, Current Liabilities, Deferred Revenue	'	'	'	'	$34,142

5_Property_Plant_and_Equipment2

5. Property, Plant and Equipment Disclosure: Schedule of Property and Equipment (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Property and equipment, net	$296,730	$266,078
Property, Plant and Equipment, Gross	520,702	891,479
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	-223,972	-625,401
Equipment	'	'
Property and equipment, net	255,339	374,229
Leaseholds and Leasehold Improvements	'	'
Property and equipment, net	145,147	402,016
Computer Software, Intangible Asset	'	'
Property and equipment, net	87,361	65,111
Furniture and Fixtures	'	'
Property and equipment, net	$32,855	$50,123

5_Property_Plant_and_Equipment3

5. Property, Plant and Equipment Disclosure (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Loss on disposal of property and equipment	$200,149	$0
Assets of Disposal Group, Including Discontinued Operation	25,832	'
Depreciation, Amortization and Accretion, Net	$97,068	$64,632

6_Patent_License_Agreement_Det

6. Patent License Agreement (Details) (USD $)	12 Months Ended		60 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2018
Details	'	'	'
Common stock shares issued in purchase of patents	'	600,000	'
Series C stock shares issued in purchase of patents	'	480,000	'
Independent valuation of patents	'	$922,378	'
Value of the Common Stock issued	'	240,000	'
Value of the Series C Preferred Stock issued	'	682,378	'
Amortization of Intangible Assets	$126,870	$147,277	$566,920

6_Patent_License_Agreement_Sch1

6. Patent License Agreement: Schedule of Expected Amortization Expense (Details) (USD $)	12 Months Ended		60 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2018
Details	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$126,870	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	126,870	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	126,870	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	59,440	'	'
Amortization of Intangible Assets	$126,870	$147,277	$566,920

7_Customer_Contracts_Details

7. Customer Contracts (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Customer contracts acquired	'	$2,369,882
Amortization	$833,032	$102,329

7_Customer_Contracts_Schedule_1

7. Customer Contracts: Schedule of Future Customer Contract Amortization (Details) (USD $)	12 Months Ended
	Sep. 30, 2013
Details	'
Future customer contract amortization year 1	$775,812
Future customer contract amortization year 2	658,709
Future customer contract amortization	$1,434,521

8_Equipment_Leased_to_Customer2

8. Equipment Leased to Customers: Schedule of leased equipment (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Property Subject to or Available for Operating Lease, Gross	$389,492	$457,898
Property Subject to or Available for Operating Lease, Accumulated Depreciation	-115,862	-144,905
Equipment leased to customers, net	$273,630	$312,993

8_Equipment_Leased_to_Customer3

8. Equipment Leased to Customers (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Property Subject To Or Available For Operating Lease Depreciation Expense	$175,049	$70,531
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$75,124	'

9_Notes_Payable_Schedule_of_De1

9. Notes Payable: Schedule of Debt (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Gross notes payable before discount	$2,863,166	$4,561,737
Discount on notes payable	-528,663	-187,587
Notes payable current and noncurrent	2,334,503	4,374,150
Notes payable current portion	-1,278,585	-2,569,221
Notes payable, net of current portion	1,055,918	1,804,929
Note1Member	'	'
Gross notes payable before discount	1,766,971	2,236,737
Note2Member	'	'
Gross notes payable before discount	550,000	'
Note3Member	'	'
Gross notes payable before discount	250,000	250,000
Note4Member	'	'
Gross notes payable before discount	185,476	'
Note5Member	'	'
Gross notes payable before discount	85,719	300,000
Note6Member	'	'
Gross notes payable before discount	25,000	275,000
Note7Member	'	'
Gross notes payable before discount	'	$1,500,000

9_Notes_Payable_Schedule_of_pr1

9. Notes Payable: Schedule of principal payments on notes payable (Details) (USD $)	12 Months Ended
	Sep. 30, 2013
Details	'
Notes payable principal payments in 2014	$1,768,820
Notes payable principal payments in 2015	854,522
Notes payable principal payments in 2016	239,824
Notes payable principal payments	$2,863,166

10_Relatedparty_Notes_Payable_1

10. Related-party Notes Payable: Schedule of related party notes payable (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Gross notes payable related party before discount	$1,896,135	$1,957,161
Discount on notes payable related party	-3,720	-223,381
Notes payable related party current and noncurrent	1,892,415	1,733,780
Notes payable related party current portion	-1,892,415	-1,563,923
Notes payable, related-party, net of current portion	0	169,857
Note1Member	'	'
Gross notes payable related party before discount	600,000	'
Note2Member	'	'
Gross notes payable related party before discount	300,000	'
Note3Member	'	'
Gross notes payable related party before discount	300,000	'
Note4Member	'	'
Gross notes payable related party before discount	200,000	'
Note5Member	'	'
Gross notes payable related party before discount	175,000	'
Note6Member	'	'
Gross notes payable related party before discount	150,000	'
Note7Member	'	'
Gross notes payable related party before discount	82,500	543,278
Note8Member	'	'
Gross notes payable related party before discount	33,000	33,000
Note9Member	'	'
Gross notes payable related party before discount	26,721	'
Note10Member	'	'
Gross notes payable related party before discount	13,644	'
Note11Member	'	'
Gross notes payable related party before discount	10,000	'
Note12Member	'	'
Gross notes payable related party before discount	5,270	'
Note13Member	'	'
Gross notes payable related party before discount	'	620,687
Note14Member	'	'
Gross notes payable related party before discount	'	300,000
Note15Member	'	'
Gross notes payable related party before discount	'	244,196
Note16Member	'	'
Gross notes payable related party before discount	'	82,500
Note17Member	'	'
Gross notes payable related party before discount	'	82,500
Note18Member	'	'
Gross notes payable related party before discount	'	$51,000

11_Loss_On_Induced_Conversion_1

11. Loss On Induced Conversion of Debt and Sale of Common Stock (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Debt and accrued interest converted to shares of common stock	$10,004,000	'
Loss on induced conversion of debt and sale of common stock	$9,355,587	$0

13_Derivative_Liabilities_Deta

13. Derivative Liabilities (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Derivatives liability	$795,151	$4,015,855
Loss on derivatives liability	$333,406	$2,104,389

14_Preferred_Stock_Details

14. Preferred Stock (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Series C stock shares issued in purchase of patents	'	480,000
Dividends payable	$3,471	$18,322
Series D preferred shares converted	50,000	'
Shares issued from conversion of Series D preferred stock	250,000	'
Accrued Dividends on Series D preferred stock	232,834	'
Series D Preferred Stock issued to settle accrued dividends	5,025	'
Shares issued to settle accrued dividends	143,465	'
Debenture loans and accrued interest converted into shares of Series E preferred stock	614,765	'
Debenture loans and accrued interest converted into shares of Series E preferred stock - shares	61,723	'
Dividends paid to Series E Shareholders	17,271	'
Redemption Price of Series E preferred stock	601,585	'
LoanOriginationFeesMember	'	'
Shares Series D Preferred Stock Issued	103,843	'
Loan origination fees	817,482	'
FutureAdvisoryServicesMember	'	'
Shares Series D Preferred Stock Issued	71,800	'
Shares Series D Preferred Stock Issued Value	230,800	'
FutureConsultingServicesMember	'	'
Shares Series D Preferred Stock Issued	20,000	'
Shares Series D Preferred Stock Issued Value	60,000	'
AccruedBoardOfDirectorFeesAndCompensationMember	'	'
Shares Series D Preferred Stock Issued	52,913	'
Shares Series D Preferred Stock Issued Value	61,652	'
BonusToAnOfficerMember	'	'
Shares Series D Preferred Stock Issued	46,300	'
Shares Series D Preferred Stock Issued Value	234,700	'
DividendsOnSeriesCPreferredStockMember	'	'
Shares Series D Preferred Stock Issued	9,062	'
Shares Series D Preferred Stock Issued Value	53,992	'
DividendsOnSeriesDPreferredStockMember	'	'
Shares Series D Preferred Stock Issued	5,025	'
Shares Series D Preferred Stock Issued Value	31,689	'
PastConsultingServicesMember	'	'
Shares Series D Preferred Stock Issued	126,117	'
Shares Series D Preferred Stock Issued Value	564,280	'
BonusForConsultingServicesMember	'	'
Shares Series D Preferred Stock Issued	85,000	'
Shares Series D Preferred Stock Issued Value	455,000	'
BonusToCeoMember	'	'
Shares Series D Preferred Stock Issued	80,000	'
Shares Series D Preferred Stock Issued Value	320,000	'
Services Member	'	'
Shares Series D Preferred Stock Issued	2,055	'
Shares Series D Preferred Stock Issued Value	14,899	'
Series C Preferred Stock	'	'
Dividends payable	$53,992	$35,763

15_Common_Stock_Details

15. Common Stock (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
ServiceCompensationMember	'	'
Common Shares Issued	327,382	'
Common Shares Issued Value	$458,929	'
CompensationForNewEmployeesMember	'	'
Common Shares Issued	220,000	'
Common Shares Issued Value	318,000	'
EmployeeBonusesMember	'	'
Common Shares Issued	27,650	'
Common Shares Issued Value	39,825	'
OptionExercisesFromEmployeeBonusesMember	'	'
Common Shares Issued	350,000	'
Common Shares Issued Value	350,000	'
EmploymentContractExtensionMember	'	'
Common Shares Issued	150,000	'
Common Shares Issued Value	187,500	'
MedicalAdvisoryBoardMembersMember	'	'
Common Shares Issued	25,000	'
Common Shares Issued Value	31,750	'
BoardMemberMember	'	'
Common Shares Issued	25,000	'
Common Shares Issued Value	31,750	'
LoanOriginationFeesMember	'	'
Common Shares Issued	141,987	100,000
Common Shares Issued Value	387,849	70,000
ExtentionOfRelatedPartyPayablesMember	'	'
Common Shares Issued	4,758	'
Common Shares Issued Value	7,137	'
ExtentionOfUnrelatedPartyPayablesMember	'	'
Common Shares Issued	40,000	'
Common Shares Issued Value	61,500	'
ConversionOfDebtMember	'	'
Common Shares Issued	13,439,190	'
Common Shares Issued Value	18,467,123	'
IssuanceOfNewDebtMember	'	'
Common Shares Issued	2,600	'
Common Shares Issued Value	3,900	'
New debt to related party	26,000	'
SettleAccruedLiabilityMember	'	'
Common Shares Issued	166,200	60,000
Common Shares Issued Value	225,300	'
Accrued Liability Settled	126,200	312,000
ConversionOfSeriesDPreferredStockMember	'	'
Common Shares Issued	250,000	'
ExerciseOfOptionsMember	'	'
Common Shares Issued	425,000	'
DividendsAccruedSeriesCAndDPreferredStockMember	'	'
Common Shares Issued	200,625	'
Common Shares Issued Value	232,765	'
Cash	'	'
Common Shares Issued	1,313,334	'
Common Shares Issued Value	1,842,334	'
Shares Issued For Cash	985,000	'
SharesToEmployeesMember	'	'
Common Shares Issued	29,600	'
PatentLicenseAgreementMember	'	'
Common Shares Issued	'	60,000
Common Shares Issued Value	'	240,000
ConsultingServicesMember	'	'
Common Shares Issued	'	129,161
Common Shares Issued Value	'	218,906
SettlementAgreementMember	'	'
Common Shares Issued	'	200,000
ShortTermNotesPayableMember	'	'
Common Shares Issued	'	231,000
Common Shares Issued Value	'	$92,400

16_Stock_Options_and_Warrants_2

16. Stock Options and Warrants: Schedule of fair value assumptions (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Minimum	'	'
Fair Value Assumptions, Exercise Price	$0.75	$0.40
Fair Value Assumptions, Expected Term	'1 year 6 months	'
Fair Value Assumptions, Expected Volatility Rate	219.00%	131.00%
Fair Value Assumptions, Risk Free Interest Rate	0.23%	0.39%
Maximum	'	'
Fair Value Assumptions, Exercise Price	$10	$0.44
Fair Value Assumptions, Expected Term	'2 years 6 months	'2 years 6 months
Fair Value Assumptions, Expected Volatility Rate	298.00%	135.00%
Fair Value Assumptions, Risk Free Interest Rate	0.88%	0.44%

16_Stock_Options_and_Warrants_3

16. Stock Options and Warrants (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Interest expense, net	$5,583,932	$858,224
Aggregate Intrinsic Value	434,890	'
Weighted average remaining term of the warrants	3.13	'
Warrant1Member	'	'
Warrants	1,300,000	'
Exercise price	$1	'
Additional compensation expense	846,898	'
Warrant2Member	'	'
Warrants	1,000,000	'
Exercise price	$1	'
Additional compensation expense	660,140	'
Warrant3Member	'	'
Warrants	425,000	'
Exercise price	$1	'
Warrant4Member	'	'
Warrants	25,300	'
Exercise price	$1	'
Additional compensation expense	32,572	'
Warrant5Member	'	'
Warrants	100,000	'
Exercise price	$1.65	'
Additional compensation expense	12,689	'
Warrant6Member	'	'
Warrants	100,000	'
Exercise price	$1	'
Interest expense, net	103,495	'
Warrant7Member	'	'
Warrants	100,000	'
Exercise price	$1	'
Consulting Expense	134,785	'
Warrant8Member	'	'
Warrants	36,667	'
Exercise price	$0.75	'
Interest expense, net	$8,317	'

16_Stock_Options_and_Warrants_4

16. Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Details	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	2,386,587	3,598,554
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$1.47	$1.33
Share-based compensation arrangement by share-based payment award, Options, Grants in period	2,086,967	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1.04	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	-875,000	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$1	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	'	2,271,887
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	'	$1.50

17_Segment_Information_Schedul1

17. Segment Information: Schedule of Segment Reporting Information, by Segment (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Total revenues	$11,399,532	$1,059,111
Net loss	-25,631,006	-12,365,756
Interest expense, net	5,583,932	858,224
Total assets	12,374,050	5,875,954
Corporate	'	'
Net loss	-11,298,372	-21,986,526
Interest expense, net	858,224	5,583,932
Total assets	397,557	600,892
Fixed assets and leased equipment purchases	93,315	243,273
Depreciation, Depletion and Amortization, Nonproduction	304,841	124,269
Chronic Illness Monitoring	'	'
Total revenues	706,888	9,738,988
Net loss	-532,207	-460,017
Total assets	1,957,779	9,482,037
Depreciation, Depletion and Amortization, Nonproduction	'	114,440
CareServices	'	'
Total revenues	352,223	1,660,544
Net loss	-389,187	-3,179,151
Total assets	3,224,579	2,291,121
Fixed assets and leased equipment purchases	257,857	241,527
Depreciation, Depletion and Amortization, Nonproduction	64,348	984,663
Reagents	'	'
Total revenues	467,259	351,645
Net loss	-145,990	-5,312
Total assets	296,039	'
Fixed assets and leased equipment purchases	'	888
Depreciation, Depletion and Amortization, Nonproduction	16,296	9,362
Total	'	'
Total revenues	1,526,370	11,751,177
Net loss	-12,365,756	-25,631,006
Interest expense, net	858,224	5,583,932
Total assets	5,875,954	12,374,050
Fixed assets and leased equipment purchases	351,172	485,688
Depreciation, Depletion and Amortization, Nonproduction	$385,485	$1,232,734

18_Income_Tax_Disclosure_Sched2

18. Income Tax Disclosure: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Deferred Tax Assets, Operating Loss Carryforwards	$19,330,000	$11,807,000
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals	453,000	101,000
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	1,863,000	1,113,000
Deferred Tax Assets, Tax Deferred Expense, Other	2,000	20,000
Deferred Tax Assets, Valuation Allowance	($21,648,000)	($13,041,000)

18_Income_Tax_Disclosure_Sched3

18. Income Tax Disclosure: Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Current Federal Tax Expense (Benefit)	$8,715,000	$4,204,000
Current State and Local Tax Expense (Benefit)	846,000	408,000
Income Tax Reconciliation, Nondeductible Expense	-954,000	-804,000
Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance	($8,607,000)	($3,808,000)

19_Commitments_and_Contingenci2

19. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	Sep. 30, 2013
Details	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$277,603
Operating Leases, Future Minimum Payments, Due in Two Years	308,330
Operating Leases, Future Minimum Payments, Due in Three Years	317,580
Operating Leases, Future Minimum Payments, Due in Four Years	327,107
Operating Leases, Future Minimum Payments, Due in Five Years	280,077
Operating Leases, Future Minimum Payments Due	$1,510,697

19_Commitments_and_Contingenci3

19. Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Details	'	'
Operating Leases, Rent Expense, Net	$268,000	$204,000

20_Subsequent_Events_Details

20. Subsequent Events (Details) (USD $)	3 Months Ended
	Dec. 31, 2013
Event 1	'
Shares issued for conversion of Series A debenture	8,347
Principal and interest balance	$83,473
Event 2	'
Shares issued for conversion of Note Payable	441,735
Principal and interest balance	331,301
Event 3	'
Preferred Stock Designated As Series F Variable Rate Convertible Preferred Stock	7,803
Proceeds From Sale of Series F Preferred Stock	2,835,771
Warrants Issued	3,495,000
Event 4	'
Shares issued for conversion of Note Payable	857
Principal and interest balance	573,868
Event 5	'
Shares issued for conversion of Note Payable	1,883,675
Principal and interest balance	1,126,026
Warrants Issued	410,348
Event 6	'
Shares issued for conversion of Note Payable	1,100,110
Principal and interest balance	659,474
Warrants Issued	239,652
Event 7	'
Shares issued for conversion of Note Payable	213,334
Principal and interest balance	160,000
Event 8	'
Series C Preferred Stock Convertible	480,000
Preferred Stock Converted To Common Stock	672,000
Event 9	'
Series D Preferred Stock Convertible	893,218
Preferred Stock Converted To Common Stock	6,252,526
Event 10	'
Shares issued for conversion of Note Payable	66,667
Principal and interest balance	$50,000